≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Other bursitis of elbow

DOID EFO Endpoint Browser PheWeb

M13_BURSELBOWOTH

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — M70.3
  • Hospital discharge: ICD-9 — 7263X
  • Cause of death: ICD-10 — M70.3
  • Cause of death: ICD-9 — 7263X

2 out of 7 registries used, show all original rules.

340

4. Check minimum number of events

None

340

5. Include endpoints

None

340

6. Filter based on genotype QC (FinnGen only)

331

Control definitions (FinnGen only)

Control exclude
M13_SOFTTISSUE

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
M70
Name in latin
Bursitis cubiti

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2048 444 1588
Only index persons 1871 413 1458
Unadjusted period prevalence (%)
Whole population 0.04 0.01 0.04
Only index persons 0.05 0.02 0.06
Median age at first event (years)
Whole population 56.06 59.81 54.95
Only index persons 55.44 58.91 54.45

-FinnGen-

Key figures

All Female Male
Number of individuals 331 92 239
Unadjusted period prevalence (%) 0.09 0.03 0.11
Median age at first event (years) 61.49 59.96 62.08

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
340
Matched controls
3400
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M70.3
ICD-10 Finland
Other bursitis of elbow
8645.5
307.7
331
7
M70.2
ICD-10 Finland
Olecranon bursitis
43.6
165.1
104
34
L10
ICPC
Elbow symptom/complaint
18.3
93.6
82
58
NCM20
NOMESCO Finland
Excision of synovial ganglion of elbow or forearm
+∞
50.3
47
*
NC1AA
NOMESCO Finland
Elbow X-ray examination without contrast
12.1
33.4
35
32
J01FF01
ATC
clindamycin; systemic
3.4
25.8
132
529
A46
ICD-10 Finland
Erysipelas
3.8
25.1
97
323
M75.1
ICD-10 Finland
Rotator cuff syndrome
3.7
23.4
91
303
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
3.0
22.3
180
923
N02AJ06
ATC
codeine and paracetamol; systemic
3.0
22.1
182
943
M79.6
ICD-10 Finland
Pain in limb
3.0
21.1
151
720
J01DB01
ATC
cefalexin; oral
5.5
20.4
312
2270
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.3
18.5
88
329
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.8
18.2
135
646
M71.0
ICD-10 Finland
Abscess of bursa
39.0
17.8
22
6
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
5.5
17.6
36
72
N03AX12
ATC
[U] gabapentin; oral
3.5
17.1
69
232
M25.5
ICD-10 Finland
Pain in joint
2.8
16.5
118
550
N02AX02
ATC
tramadol; systemic, rectal
2.6
16.3
165
910
R4110
NOMESCO Finland
Physiotherapy
2.7
16.3
122
581
M13.9
ICD-10 Finland
Arthritis, unspecified
4.6
15.8
40
96
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.6
15.6
58
184
M71.9
ICD-10 Finland
Bursopathy, unspecified
40.1
15.5
19
5
L03.1
ICD-10 Finland
Cellulitis of other parts of limb
6.3
15.5
27
46
Z71.8
ICD-10 Finland
Other specified counselling
2.6
15.5
135
690
M48.0
ICD-10 Finland
Spinal stenosis
3.5
14.7
58
191
M71.1
ICD-10 Finland
Other infective bursitis
+∞
14.7
14
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.7
14.5
105
487
X59
ICD-10 Finland
Exposure to unspecified factor
2.9
14.5
80
322
S18
ICPC
Laceration/cut
2.4
14.3
189
1158
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
3.6
14.3
53
168
L17
ICPC
Foot/toe symptom/complaint
2.5
14.1
120
602
WX320
NOMESCO Finland
Spinalanesthesy
2.6
13.9
103
482
N03AX16
ATC
[U] pregabalin
2.8
13.9
85
361
Z3226
NOMESCO Finland
Physiotherapist
2.9
13.7
74
294
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
4.7
13.7
33
76
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
4.7
13.4
32
73
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
4.1
13.1
38
101
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
3.4
13.0
52
173
WX402
NOMESCO Finland
General anaesthesia
2.5
12.5
97
462
R52.9
ICD-10 Finland
Pain, unspecified
3.5
12.4
46
145
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.9
12.4
65
253
L04AA13
ATC
[U] leflunomide
14.1
12.1
20
15
M10.9
ICD-10 Finland
Gout, unspecified
3.4
11.9
45
144
L04AX03
ATC
methotrexate; systemic
3.5
11.9
44
139
NBG15
NOMESCO Finland
Acromioplastia, arthroscopic
14.3
11.6
19
14
X58
ICD-10 Finland
Exposure to other specified factors
2.8
11.6
64
256
A02BC02
ATC
pantoprazole; systemic
2.4
11.5
246
1782
H02AB06
ATC
prednisolone; systemic
2.2
11.4
175
1108
SPAT1144
SPAT
Treatment of reopened or infected surgical wound
3.8
11.4
36
102
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.4
11.3
44
143
M04AA01
ATC
allopurinol; systemic
2.7
11.3
72
310
S21
ICPC
Skin texture symptom/complaint
2.8
11.3
66
272
L08
ICPC
Shoulder symptom/complaint
2.6
11.2
80
365
S46.0
ICD-10 Finland
Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder
3.6
11.0
38
114
WX002
NOMESCO Finland
Sedation and analgesia
2.5
11.0
80
367
J01CF05
ATC
flucloxacillin; systemic
3.4
11.0
42
135
L12
ICPC
Hand/finger symptom/complaint
2.8
10.9
64
264
M19.0
ICD-10 Finland
Primary arthrosis of other joints
3.7
10.9
37
110
M01AH05
ATC
etoricoxib; oral
2.2
10.8
214
1484
N02BF02
ATC
pregabalin; oral
4.2
10.8
30
77
M67.4
ICD-10 Finland
Ganglion
5.5
10.7
21
40
QDB05
NOMESCO Finland
Revision of wound of skin of lower limb
5.5
10.7
21
40
L03
ICPC
Low back symptom/complaint
2.3
10.5
97
495
ZXD35
NOMESCO Finland
Usual procedure
5.4
10.4
21
41
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.3
10.3
41
135
Z2221
NOMESCO Finland
Medical doctor
2.3
10.3
100
521
SPAT1255
SPAT
Intravenous administration of medicine
3.7
10.3
34
99
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.2
10.3
43
146
ZXE10
NOMESCO Finland
More than one and less than three hours
2.2
10.2
128
741
M10.0
ICD-10 Finland
Idiopathic gout
4.3
10.2
27
67
ZXD20
NOMESCO Finland
Day surgery
3.0
10.1
48
176
L01BA01
ATC
methotrexate; systemic
8.5
10.0
21
26
ZXE00
NOMESCO Finland
One hour or less
2.1
10.0
133
787
N02BF01
ATC
gabapentin; oral
3.4
9.8
37
118
J01DA01
ATC
[U] cefalexin
2.1
9.7
206
1443
M03BX02
ATC
tizanidine; oral
2.1
9.7
206
1443
M75.4
ICD-10 Finland
Impingement syndrome of shoulder
11.9
9.7
17
15
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
2.8
9.6
54
217
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
4.6
9.5
23
53
L28
ICPC
Limited function/disability (L)
2.5
9.5
71
329
D07AC01
ATC
betamethasone; topical
2.1
9.5
136
824
S29
ICPC
Skin symptom/complaint other
2.4
9.4
81
399
D07BA04
ATC
hydrocortisone and antiseptics; topical
3.1
9.3
42
149
L87
ICPC
Bursitis/tendinitis/synovitis NOS
14.2
9.3
15
11
M01AH01
ATC
celecoxib; oral
2.5
9.2
63
279
NGB20
NOMESCO Finland
Primary total prosthetic replacement of knee joint without patellar part
2.9
9.2
45
168
N06AX21
ATC
duloxetine; oral
3.2
9.2
39
134
G56.0
ICD-10 Finland
Carpal tunnel syndrome
3.0
9.1
43
157
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
3.8
9.0
28
78
Z3231
NOMESCO Finland
Registered nurse
2.1
8.9
106
595
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
3.8
8.9
28
79
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.4
8.9
68
318
ZXD10
NOMESCO Finland
Scheduled procedure
2.0
8.8
131
799
M17
ICD-10 Finland
Gonarthrosis [arthrosis of knee]
2.9
8.8
45
172
H02AB07
ATC
prednisone; oral
2.7
8.7
50
203
M20.4
ICD-10 Finland
Other hammer toe(s) (acquired)
4.8
8.7
20
44
ZXD05
NOMESCO Finland
Urgent procedure
2.1
8.7
111
641
P01BA02
ATC
hydroxychloroquine; oral
3.5
8.6
31
96
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
3.7
8.6
28
81
R4120
NOMESCO Finland
Occupational therapy
3.6
8.6
29
86
EB1AA
NOMESCO Finland
Intraoral radiographic dental examination
2.0
8.5
185
1286
Z76.0
ICD-10 Finland
Issue of repeat prescription
2.1
8.5
97
536
L88
ICPC
Rheumatoid/seropositive arthritis
4.8
8.5
19
41
L02.4
ICD-10 Finland
Cutaneous abscess, furuncle and carbuncle of limb
4.3
8.4
22
54
7263X
ICD-9 Finland
Peripheral enthesopathies and allied syndromes, Enthesopathy of elbow region[ENTHESOPATHIA OLECRANI ALIA SEU NUD]
+∞
8.4
8
*
M54.5
ICD-10 Finland
Low back pain
2.0
8.3
115
681
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
3.7
8.3
27
78
ZXA05
NOMESCO Finland
Left side
2.2
8.3
83
435
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.4
8.3
61
280
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.0
8.2
110
644
WX110
NOMESCO Finland
Infiltration anesthesia
2.0
8.0
240
1843
S97
ICPC
Chronic ulcer skin
3.1
7.9
35
123
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
2.5
7.8
52
227
M75.9
ICD-10 Finland
Shoulder lesion, unspecified
4.5
7.8
19
44
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.0
7.8
36
130
NBL22
NOMESCO Finland
Myotomy, tenotomy or excision of tendon of upper arm
46.1
7.7
9
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.2
7.6
73
374
U07
ICPC
Urine symptom/complaint other
3.0
7.6
34
120
NGD05
NOMESCO Finland
Partial excision of meniscus of knee, arthroscopic
2.6
7.6
47
198
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
3.4
7.6
28
88
M03BC01
ATC
orphenadrine (citrate); systemic
2.2
7.5
73
376
NBL00
NOMESCO Finland
Suture or reinsertation of rotator cuff of shoulder
4.6
7.5
18
41
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
6.7
7.5
18
28
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
7.9
7.5
16
21
NDM10
NOMESCO Finland
Palmar fasciotomy of hand
81.8
7.4
8
*
M79.2
ICD-10 Finland
Neuralgia and neuritis, unspecified
13.8
7.4
12
9
ZXA00
NOMESCO Finland
Right side
2.1
7.4
90
505
A02BC01
ATC
omeprazole; systemic
2.1
7.4
91
513
M17.1
ICD-10 Finland
Other primary gonarthrosis
2.2
7.4
72
371
B01AF02
ATC
apixaban; oral
2.3
7.2
57
269
D07AB02
ATC
hydrocortisone butyrate; topical
2.0
7.2
105
629
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.3
7.2
63
311
ZXE20
NOMESCO Finland
More than three and less than five hours
2.4
7.2
55
256
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.1
7.2
30
102
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
2.7
7.2
41
166
ND1AA
NOMESCO Finland
Wrist X-ray examination
3.3
7.2
27
86
ZZH21
NOMESCO Finland
Graft of patients own bone, small pieces
10.3
7.1
13
13
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
7.2
7.1
16
23
TPH07
NOMESCO Finland
Cathetrisation of artery
2.4
7.1
51
231
Z3229
NOMESCO Finland
Other healthcare associate professional
2.8
7.1
36
137
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.6
7.0
23
67
N02AA05
ATC
oxycodone; systemic
2.1
7.0
73
387
M54.3
ICD-10 Finland
Sciatica
3.5
7.0
24
72
EB1AA, ,
SPAT
3.1
6.9
29
99
N02BE01
ATC
paracetamol; systemic, rectal
2.5
6.9
302
2587
XF400
NOMESCO Finland
ECG with 12 standard connections
2.2
6.8
62
310
J01CE02
ATC
phenoxymethylpenicillin; oral
1.9
6.8
229
1779
L15
ICPC
Knee symptom/complaint
2.0
6.8
80
444
NGF35
NOMESCO Finland
Plastic operation of joint cartilage of knee
6.1
6.7
17
29
W00
ICD-10 Finland
Fall on same level involving ice and snow
2.6
6.7
42
178
M01AB05
ATC
diclofenac; systemic, rectal
1.8
6.7
215
1643
M01AE03
ATC
ketoprofen; systemic, rectal
1.9
6.6
118
752
A01
ICPC
Pain general/multiple sites
2.7
6.6
36
142
GD1LA
NOMESCO Finland
GD
9.0
6.6
13
15
WX203
NOMESCO Finland
Infraclavicular plexus blockade
7.1
6.6
15
22
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.9
6.6
104
638
R03BB04
ATC
tiotropium bromide; inhalant
2.5
6.6
45
199
R60.0
ICD-10 Finland
Localized oedema
2.5
6.6
45
199
J45.9
ICD-10 Finland
Asthma, unspecified
2.1
6.5
67
352
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.1
6.4
67
354
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.9
6.4
30
109
R42
ICD-10 Finland
Dizziness and giddiness
2.0
6.4
80
452
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
3.5
6.4
22
66
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
5.7
6.4
17
31
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.1
6.4
70
377
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.0
6.4
76
422
WX202
NOMESCO Finland
Supraclavicular plexus blockade
9.5
6.3
12
13
XF600
NOMESCO Finland
Bloodpressure measurement
3.1
6.3
27
93
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
3.1
6.3
26
88
NC1BG
NOMESCO Finland
Elbow MRI examination with high intensity magnet
27.2
6.3
8
*
M15.9
ICD-10 Finland
Polyarthrosis, unspecified
3.4
6.3
22
67
M75.0
ICD-10 Finland
Adhesive capsulitis of shoulder
5.5
6.2
17
32
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
6.2
170
1227
J01MA02
ATC
ciprofloxacin; systemic
1.8
6.2
134
903
WX704
NOMESCO Finland
Intubation
2.7
6.2
33
129
M54.1
ICD-10 Finland
Radiculopathy
4.3
6.2
16
39
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.3
6.2
48
225
AA1AD
NOMESCO Finland
CT of head and brain
1.9
6.1
106
667
R20.2
ICD-10 Finland
Paraesthesia of skin
3.1
6.1
25
84
E0000UV, ,
ATC
1.8
6.1
134
907
S76
ICPC
Skin infection other
2.9
6.1
28
101
A97
ICPC
No disease
2.0
6.0
74
415

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
pregabalin; oral
N02BF02 [955152]
1.3e+00
1.7e+00
2.8e+00
—
2.5e+00
1.6e+00
1.4e+00
cases:7.67%
controls:2.15%
cases:5.60%
controls:1.03%
cases:2.95%
controls:0.18%
—
—
cases:3.25%
controls:0.27%
cases:6.60%
controls:1.43%
cases:8.54%
controls:2.26%
26
73
313
3317
19
35
320
3355
10
6
329
3384
—
11
9
327
3370
21
46
297
3176
21
56
225
2421
cefalexin; oral
J01DB01 [21602870]
7.1e-01
1.4e+00
3.2e+00
—
3.6e+00
1.0e+00
1.2e+00
cases:39.82%
controls:24.48%
cases:23.30%
controls:7.02%
cases:15.04%
controls:0.74%
—
—
cases:24.85%
controls:0.89%
cases:18.55%
controls:7.51%
cases:49.19%
controls:22.12%
135
830
204
2560
79
238
260
3152
51
25
288
3365
—
84
30
254
3349
59
242
259
2980
121
548
125
1929
Orthopedic Surgery
20 [38004465]
1.2e+00
1.5e+00
2.2e+00
1.0e+50
2.7e+00
1.7e+00
1.2e+00
cases:27.14%
controls:10.53%
cases:13.86%
controls:3.48%
cases:5.01%
controls:0.59%
cases:12.39%
controls:0.00%
cases:7.99%
controls:0.59%
cases:17.61%
controls:3.85%
cases:29.27%
controls:10.82%
92
357
247
3033
47
118
292
3272
17
20
322
3370
42
0
297
3390
27
20
311
3359
56
124
262
3098
72
268
174
2209
Bacteria identified in Blood by Culture
600-7 [3023368]
8.3e-01
1.3e+00
2.9e+00
1.0e+50
3.5e+00
1.0e+00
9.4e-01
cases:11.80%
controls:5.52%
cases:6.49%
controls:1.86%
cases:4.42%
controls:0.27%
cases:9.44%
controls:0.00%
cases:6.21%
controls:0.21%
cases:7.86%
controls:3.01%
cases:15.45%
controls:6.66%
40
187
299
3203
22
63
317
3327
15
9
324
3381
32
0
307
3390
21
7
317
3372
25
97
293
3125
38
165
208
2312
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
4.4e-01
6.0e-01
1.4e+00
4.3e+00
1.8e+00
7.3e-01
5.0e-01
cases:43.36%
controls:33.04%
cases:35.40%
controls:23.13%
cases:16.81%
controls:4.84%
cases:15.93%
controls:0.27%
cases:22.19%
controls:4.47%
cases:36.79%
controls:21.91%
cases:46.75%
controls:34.68%
147
1120
192
2270
120
784
219
2606
57
164
282
3226
54
9
285
3381
75
151
263
3228
117
706
201
2516
115
859
131
1618
Other psoriatic arthropathies
M07.3*L40.5 [2000503010]
1.9e+00
2.8e+00
—
—
—
2.5e+00
2.3e+00
cases:2.36%
controls:0.35%
cases:2.36%
controls:0.15%
—
—
—
—
—
—
cases:2.20%
controls:0.19%
cases:2.44%
controls:0.24%
8
12
331
3378
8
5
331
3385
—
—
—
7
6
311
3216
6
6
240
2471
Rheumatology
66 [38004491]
1.4e+00
1.9e+00
—
1.0e+50
2.7e+00
1.9e+00
1.5e+00
cases:8.85%
controls:2.24%
cases:7.37%
controls:1.15%
—
—
cases:2.65%
controls:0.00%
cases:2.66%
controls:0.18%
cases:7.55%
controls:1.24%
cases:8.94%
controls:2.06%
30
76
309
3314
25
39
314
3351
—
9
0
330
3390
9
6
329
3373
24
40
294
3182
22
51
224
2426
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
5.0e-01
7.2e-01
1.3e+00
4.6e+00
1.7e+00
6.8e-01
4.2e-01
cases:40.12%
controls:28.88%
cases:36.58%
controls:21.98%
cases:15.63%
controls:4.78%
cases:15.34%
controls:0.18%
cases:20.71%
controls:4.68%
cases:35.53%
controls:21.85%
cases:42.68%
controls:32.86%
136
979
203
2411
124
745
215
2645
53
162
286
3228
52
6
287
3384
70
158
268
3221
113
704
205
2518
105
814
141
1663
Olecranon bursitis
M70.2 [45557961]
3.1e+00
—
1.0e+50
1.0e+50
1.0e+50
4.0e+00
2.2e+00
cases:3.83%
controls:0.18%
—
—
cases:7.08%
controls:0.00%
cases:7.67%
controls:0.00%
cases:9.76%
controls:0.00%
cases:9.12%
controls:0.19%
cases:4.07%
controls:0.44%
13
6
326
3384
—
24
0
315
3390
26
0
313
3390
33
0
305
3379
29
6
289
3216
10
11
236
2466
Elbow symptom/complaint
L10 [2002000634]
2.6e+00
3.7e+00
—
1.0e+50
—
2.3e+00
1.7e+00
cases:2.95%
controls:0.24%
cases:5.90%
controls:0.15%
—
—
cases:3.54%
controls:0.00%
—
—
cases:2.20%
controls:0.22%
cases:2.44%
controls:0.44%
10
8
329
3382
20
5
319
3385
—
12
0
327
3390
—
7
7
311
3215
6
11
240
2466
General Surgery
2 [38004447]
7.4e-01
1.2e+00
1.6e+00
1.0e+50
2.8e+00
1.2e+00
9.7e-01
cases:24.78%
controls:13.57%
cases:12.98%
controls:4.25%
cases:3.24%
controls:0.65%
cases:23.30%
controls:0.00%
cases:5.92%
controls:0.38%
cases:12.58%
controls:4.03%
cases:26.83%
controls:12.19%
84
460
255
2930
44
144
295
3246
11
22
328
3368
79
0
260
3390
20
13
318
3366
40
130
278
3092
66
302
180
2175
Outpatient Visit
OP [9202]
7.6e-01
7.0e-01
4.0e-01
4.7e+00
9.1e-01
5.0e-01
9.9e-01
cases:81.71%
controls:67.73%
cases:65.78%
controls:48.91%
cases:14.45%
controls:10.21%
cases:25.96%
controls:0.32%
cases:20.41%
controls:9.32%
cases:59.43%
controls:46.93%
cases:86.59%
controls:70.61%
277
2296
62
1094
223
1658
116
1732
49
346
290
3044
88
11
251
3379
69
315
269
3064
189
1512
129
1710
213
1749
33
728
General Practice
1 [38004446]
9.2e-01
1.2e+00
1.6e+00
1.0e+50
2.6e+00
1.2e+00
9.1e-01
cases:23.30%
controls:10.80%
cases:11.50%
controls:3.63%
cases:3.24%
controls:0.65%
cases:14.16%
controls:0.00%
cases:7.10%
controls:0.56%
cases:14.47%
controls:5.00%
cases:28.05%
controls:13.52%
79
366
260
3024
39
123
300
3267
11
22
328
3368
48
0
291
3390
24
19
314
3360
46
161
272
3061
69
335
177
2142
Laceration/cut
S18 [2002000983]
5.1e-01
8.4e-01
2.3e+00
—
2.8e+00
1.4e+00
1.0e+00
cases:11.50%
controls:7.26%
cases:6.49%
controls:2.92%
cases:4.72%
controls:0.47%
—
—
cases:6.21%
controls:0.41%
cases:10.69%
controls:2.95%
cases:21.54%
controls:9.08%
39
246
300
3144
22
99
317
3291
16
16
323
3374
—
21
14
317
3365
34
95
284
3127
53
225
193
2252
Emergency Medicine
93 [38004510]
5.5e-01
1.1e+00
2.2e+00
—
2.7e+00
1.1e+00
6.3e-01
cases:24.48%
controls:15.72%
cases:18.29%
controls:7.02%
cases:8.26%
controls:0.94%
—
—
cases:10.06%
controls:0.77%
cases:19.81%
controls:7.76%
cases:31.71%
controls:19.82%
83
533
256
2857
62
238
277
3152
28
32
311
3358
—
34
26
304
3353
63
250
255
2972
78
491
168
1986
Emergency Room Visit
ER [9203]
8.2e-01
9.5e-01
1.7e+00
—
2.4e+00
1.2e+00
1.1e+00
cases:46.31%
controls:27.43%
cases:19.76%
controls:8.73%
cases:5.01%
controls:0.97%
—
—
cases:8.28%
controls:0.80%
cases:22.96%
controls:8.29%
cases:50.41%
controls:24.75%
157
930
182
2460
67
296
272
3094
17
33
322
3357
—
28
27
310
3352
73
267
245
2955
124
613
122
1864
prednisolone; oral, parenteral
H02AB06 [21602734]
1.0e+00
1.5e+00
1.4e+00
—
1.5e+00
1.6e+00
1.2e+00
cases:21.24%
controls:8.94%
cases:15.93%
controls:4.10%
cases:2.95%
controls:0.74%
—
—
cases:4.44%
controls:1.04%
cases:16.67%
controls:3.85%
cases:25.20%
controls:9.41%
72
303
267
3087
54
139
285
3251
10
25
329
3365
—
15
35
323
3344
53
124
265
3098
62
233
184
2244
prednisolone
A07EA01 [21600653]
1.0e+00
1.5e+00
1.4e+00
—
1.5e+00
1.6e+00
1.2e+00
cases:21.24%
controls:9.00%
cases:15.93%
controls:4.13%
cases:2.95%
controls:0.74%
—
—
cases:4.44%
controls:1.04%
cases:16.67%
controls:3.85%
cases:25.20%
controls:9.49%
72
305
267
3085
54
140
285
3250
10
25
329
3365
—
15
35
323
3344
53
124
265
3098
62
235
184
2242
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.4e-01
2.0e-01
1.2e+00
4.9e+00
1.4e+00
4.7e-01
3.5e-01
cases:44.84%
controls:38.97%
cases:33.92%
controls:29.53%
cases:14.75%
controls:5.19%
cases:16.81%
controls:0.15%
cases:19.23%
controls:5.30%
cases:38.36%
controls:27.96%
cases:52.03%
controls:43.44%
152
1321
187
2069
115
1001
224
2389
50
176
289
3214
57
5
282
3385
65
179
273
3200
122
901
196
2321
128
1076
118
1401
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.5e-01
2.2e-01
1.1e+00
4.9e+00
1.4e+00
5.3e-01
3.4e-01
cases:45.13%
controls:39.14%
cases:34.51%
controls:29.73%
cases:14.45%
controls:5.34%
cases:16.52%
controls:0.15%
cases:19.23%
controls:5.45%
cases:40.25%
controls:28.31%
cases:52.03%
controls:43.64%
153
1327
186
2063
117
1008
222
2382
49
181
290
3209
56
5
283
3385
65
184
273
3195
128
912
190
2310
128
1081
118
1396
methotrexate; oral, parenteral
L04AX03 [21603929]
1.8e+00
1.5e+00
1.7e+00
—
—
1.4e+00
1.6e+00
cases:7.96%
controls:1.47%
cases:5.31%
controls:1.21%
cases:2.36%
controls:0.44%
—
—
—
—
cases:4.72%
controls:1.24%
cases:6.10%
controls:1.29%
27
50
312
3340
18
41
321
3349
8
15
331
3375
—
—
15
40
303
3182
15
32
231
2445
methotrexate
L01BA01 [21601423]
1.8e+00
1.5e+00
1.7e+00
—
—
1.4e+00
1.6e+00
cases:7.96%
controls:1.47%
cases:5.31%
controls:1.21%
cases:2.36%
controls:0.44%
—
—
—
—
cases:4.72%
controls:1.24%
cases:6.10%
controls:1.29%
27
50
312
3340
18
41
321
3349
8
15
331
3375
—
—
15
40
303
3182
15
32
231
2445
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
7.5e-01
1.1e+00
2.0e+00
—
2.2e+00
9.3e-01
8.8e-01
cases:12.98%
controls:6.58%
cases:8.85%
controls:3.19%
cases:2.36%
controls:0.32%
—
—
cases:2.37%
controls:0.27%
cases:6.29%
controls:2.58%
cases:14.23%
controls:6.42%
44
223
295
3167
30
108
309
3282
8
11
331
3379
—
8
9
330
3370
20
83
298
3139
35
159
211
2318
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
6.8e-01
8.3e-01
1.1e+00
2.5e+00
1.1e+00
8.3e-01
6.3e-01
cases:25.96%
controls:15.13%
cases:18.29%
controls:8.91%
cases:5.60%
controls:1.98%
cases:1.77%
controls:0.15%
cases:6.21%
controls:2.22%
cases:16.98%
controls:8.16%
cases:26.42%
controls:16.03%
88
513
251
2877
62
302
277
3088
19
67
320
3323
6
5
333
3385
21
75
317
3304
54
263
264
2959
65
397
181
2080
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.0e-01
3.1e-01
1.1e+00
4.2e+00
1.4e+00
4.2e-01
2.3e-01
cases:47.79%
controls:45.19%
cases:42.77%
controls:35.52%
cases:19.47%
controls:7.61%
cases:18.29%
controls:0.32%
cases:24.85%
controls:7.37%
cases:44.34%
controls:34.39%
cases:55.28%
controls:49.54%
162
1532
177
1858
145
1204
194
2186
66
258
273
3132
62
11
277
3379
84
249
254
3130
141
1108
177
2114
136
1227
110
1250
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.0e-01
3.1e-01
1.1e+00
4.2e+00
1.4e+00
4.2e-01
2.3e-01
cases:47.79%
controls:45.22%
cases:42.77%
controls:35.52%
cases:19.47%
controls:7.61%
cases:17.99%
controls:0.32%
cases:24.85%
controls:7.37%
cases:44.34%
controls:34.39%
cases:55.28%
controls:49.54%
162
1533
177
1857
145
1204
194
2186
66
258
273
3132
61
11
278
3379
84
249
254
3130
141
1108
177
2114
136
1227
110
1250
MCH [Entitic mass]
28539-5 [3035941]
1.1e-01
3.1e-01
1.1e+00
4.2e+00
1.4e+00
4.2e-01
2.3e-01
cases:47.79%
controls:45.16%
cases:42.77%
controls:35.52%
cases:19.47%
controls:7.61%
cases:17.99%
controls:0.32%
cases:24.85%
controls:7.37%
cases:44.34%
controls:34.39%
cases:55.28%
controls:49.54%
162
1531
177
1859
145
1204
194
2186
66
258
273
3132
61
11
278
3379
84
249
254
3130
141
1108
177
2114
136
1227
110
1250
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.0e-01
3.1e-01
1.1e+00
4.2e+00
1.4e+00
4.2e-01
2.3e-01
cases:47.79%
controls:45.22%
cases:42.77%
controls:35.52%
cases:19.47%
controls:7.64%
cases:17.99%
controls:0.32%
cases:24.85%
controls:7.37%
cases:44.34%
controls:34.39%
cases:55.28%
controls:49.58%
162
1533
177
1857
145
1204
194
2186
66
259
273
3131
61
11
278
3379
84
249
254
3130
141
1108
177
2114
136
1228
110
1249
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
9.9e-01
1.2e+00
2.3e+00
—
1.8e+00
1.4e+00
1.1e+00
cases:9.44%
controls:3.72%
cases:6.19%
controls:1.86%
cases:1.77%
controls:0.18%
—
—
cases:1.78%
controls:0.30%
cases:6.29%
controls:1.55%
cases:10.16%
controls:3.59%
32
126
307
3264
21
63
318
3327
6
6
333
3384
—
6
10
332
3369
20
50
298
3172
25
89
221
2388
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.0e-01
3.1e-01
1.1e+00
4.2e+00
1.4e+00
4.2e-01
2.3e-01
cases:47.79%
controls:45.22%
cases:42.77%
controls:35.52%
cases:19.47%
controls:7.67%
cases:17.99%
controls:0.32%
cases:24.85%
controls:7.40%
cases:44.34%
controls:34.45%
cases:55.28%
controls:49.66%
162
1533
177
1857
145
1204
194
2186
66
260
273
3130
61
11
278
3379
84
250
254
3129
141
1110
177
2112
136
1230
110
1247
Platelets [#/volume] in Blood
26515-7 [3007461]
1.1e-01
3.0e-01
1.1e+00
4.2e+00
1.4e+00
4.2e-01
2.3e-01
cases:47.79%
controls:45.01%
cases:42.48%
controls:35.46%
cases:19.17%
controls:7.64%
cases:17.70%
controls:0.32%
cases:24.56%
controls:7.37%
cases:44.34%
controls:34.39%
cases:55.28%
controls:49.50%
162
1526
177
1864
144
1202
195
2188
65
259
274
3131
60
11
279
3379
83
249
255
3130
141
1108
177
2114
136
1226
110
1251
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.0e-01
3.0e-01
1.1e+00
4.2e+00
1.4e+00
4.2e-01
2.3e-01
cases:47.79%
controls:45.25%
cases:42.77%
controls:35.58%
cases:19.17%
controls:7.61%
cases:17.70%
controls:0.32%
cases:24.56%
controls:7.40%
cases:44.34%
controls:34.39%
cases:55.28%
controls:49.58%
162
1534
177
1856
145
1206
194
2184
65
258
274
3132
60
11
279
3379
83
250
255
3129
141
1108
177
2114
136
1228
110
1249
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.4e-01
2.0e-01
1.0e+00
4.2e+00
1.3e+00
4.6e-01
2.7e-01
cases:46.31%
controls:42.74%
cases:38.35%
controls:33.69%
cases:17.11%
controls:6.87%
cases:17.11%
controls:0.29%
cases:20.71%
controls:6.72%
cases:42.77%
controls:32.15%
cases:54.07%
controls:47.23%
157
1449
182
1941
130
1142
209
2248
58
233
281
3157
58
10
281
3380
70
227
268
3152
136
1036
182
2186
133
1170
113
1307
Bacteria [Presence] in Urine
87829-8 [36304419]
8.0e-01
8.2e-01
2.0e+00
—
2.0e+00
1.1e+00
1.1e+00
cases:12.68%
controls:6.11%
cases:6.19%
controls:2.83%
cases:2.06%
controls:0.29%
—
—
cases:2.07%
controls:0.30%
cases:7.23%
controls:2.51%
cases:15.04%
controls:5.53%
43
207
296
3183
21
96
318
3294
7
10
332
3380
—
7
10
331
3369
23
81
295
3141
37
137
209
2340
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
9.4e-01
1.1e+00
2.3e+00
—
1.8e+00
1.3e+00
1.1e+00
cases:9.14%
controls:3.78%
cases:5.90%
controls:2.04%
cases:1.77%
controls:0.18%
—
—
cases:1.78%
controls:0.30%
cases:6.29%
controls:1.74%
cases:11.38%
controls:4.00%
31
128
308
3262
20
69
319
3321
6
6
333
3384
—
6
10
332
3369
20
56
298
3166
28
99
218
2378
Emergency Room and Inpatient Visit
ERIP [262]
6.6e-01
4.4e-01
1.9e+00
—
2.7e+00
8.1e-01
7.5e-01
cases:12.09%
controls:6.67%
cases:5.01%
controls:3.27%
cases:2.36%
controls:0.35%
—
—
cases:4.14%
controls:0.30%
cases:7.86%
controls:3.66%
cases:17.48%
controls:9.12%
41
226
298
3164
17
111
322
3279
8
12
331
3378
—
14
10
324
3369
25
118
293
3104
43
226
203
2251
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
9.8e-01
1.2e+00
—
—
2.2e+00
1.3e+00
1.0e+00
cases:11.50%
controls:4.63%
cases:6.49%
controls:2.06%
—
—
—
—
cases:2.37%
controls:0.27%
cases:6.29%
controls:1.77%
cases:10.98%
controls:4.16%
39
157
300
3233
22
70
317
3320
—
—
8
9
330
3370
20
57
298
3165
27
103
219
2374
Leukocytes [#/volume] in Urine
30405-5 [3018095]
7.0e-01
7.7e-01
1.8e+00
—
1.7e+00
8.8e-01
7.9e-01
cases:15.04%
controls:8.08%
cases:9.14%
controls:4.45%
cases:3.24%
controls:0.53%
—
—
cases:2.96%
controls:0.53%
cases:9.43%
controls:4.16%
cases:17.89%
controls:9.00%
51
274
288
3116
31
151
308
3239
11
18
328
3372
—
10
18
328
3361
30
134
288
3088
44
223
202
2254
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
7.0e-01
1.2e+00
1.6e+00
—
2.4e+00
1.2e+00
9.3e-01
cases:11.50%
controls:6.05%
cases:6.78%
controls:2.06%
cases:2.06%
controls:0.44%
—
—
cases:3.25%
controls:0.30%
cases:6.92%
controls:2.11%
cases:11.79%
controls:5.01%
39
205
300
3185
23
70
316
3320
7
15
332
3375
—
11
10
327
3369
22
68
296
3154
29
124
217
2353
Case Management Agency
251B00000X [38004193]
1.4e-01
2.2e-01
1.0e+00
4.1e+00
1.1e+00
2.7e-01
1.7e-01
cases:67.55%
controls:64.40%
cases:62.83%
controls:57.49%
cases:46.31%
controls:23.81%
cases:45.72%
controls:1.33%
cases:49.70%
controls:24.12%
cases:64.78%
controls:58.44%
cases:73.58%
controls:70.08%
229
2183
110
1207
213
1949
126
1441
157
807
182
2583
155
45
184
3345
168
815
170
2564
206
1883
112
1339
181
1736
65
741
Pharmacy visit
OMOP4822462 [581458]
4.7e-01
8.5e-01
7.6e-01
2.6e+00
1.1e+00
8.5e-01
3.3e-01
cases:94.69%
controls:91.74%
cases:91.15%
controls:81.50%
cases:65.19%
controls:46.78%
cases:20.65%
controls:1.92%
cases:72.19%
controls:46.05%
cases:91.82%
controls:82.71%
cases:95.53%
controls:93.90%
321
3110
18
280
309
2763
30
627
221
1586
118
1804
70
65
269
3325
244
1556
94
1823
292
2665
26
557
235
2326
11
151
Asthma, unspecified
J45.9 [45562456]
5.2e-01
1.3e+00
—
—
2.0e+00
1.4e+00
1.4e+00
cases:4.72%
controls:2.86%
cases:4.72%
controls:1.33%
—
—
—
—
cases:1.78%
controls:0.24%
cases:5.66%
controls:1.43%
cases:12.20%
controls:3.43%
16
97
323
3293
16
45
323
3345
—
—
6
8
332
3371
18
46
300
3176
30
85
216
2392
ibuprofen
R02AX02 [1588667]
5.2e-01
6.6e-01
1.4e+00
—
1.9e+00
7.5e-01
7.8e-01
cases:40.71%
controls:28.91%
cases:21.53%
controls:12.42%
cases:7.37%
controls:1.86%
—
—
cases:8.58%
controls:1.33%
cases:20.75%
controls:10.99%
cases:43.90%
controls:26.40%
138
980
201
2410
73
421
266
2969
25
63
314
3327
—
29
45
309
3334
66
354
252
2868
108
654
138
1823
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
5.2e-01
6.6e-01
1.4e+00
—
1.9e+00
7.5e-01
7.8e-01
cases:40.71%
controls:28.91%
cases:21.53%
controls:12.42%
cases:7.37%
controls:1.86%
—
—
cases:8.58%
controls:1.33%
cases:20.75%
controls:10.99%
cases:43.90%
controls:26.40%
138
980
201
2410
73
421
266
2969
25
63
314
3327
—
29
45
309
3334
66
354
252
2868
108
654
138
1823
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
1.3e-01
1.1e-01
1.0e+00
3.8e+00
1.2e+00
3.0e-01
3.0e-01
cases:34.81%
controls:31.86%
cases:28.02%
controls:25.81%
cases:12.98%
controls:5.04%
cases:11.80%
controls:0.29%
cases:15.38%
controls:5.03%
cases:30.50%
controls:24.46%
cases:43.09%
controls:35.89%
118
1080
221
2310
95
875
244
2515
44
171
295
3219
40
10
299
3380
52
170
286
3209
97
788
221
2434
106
889
140
1588
Laboratory Visit
OMOP4822461 [32036]
-1.8e-02
2.6e-01
9.2e-01
4.0e+00
1.1e+00
2.9e-01
1.1e-01
cases:48.67%
controls:49.12%
cases:49.56%
controls:43.04%
cases:28.61%
controls:13.78%
cases:25.96%
controls:0.62%
cases:32.25%
controls:13.55%
cases:50.00%
controls:42.89%
cases:56.10%
controls:53.41%
165
1665
174
1725
168
1459
171
1931
97
467
242
2923
88
21
251
3369
109
458
229
2921
159
1382
159
1840
138
1323
108
1154
Arthritis, unspecified
M13.9 [45567463]
1.5e+00
2.5e+00
—
—
—
—
2.0e+00
cases:3.54%
controls:0.80%
cases:2.36%
controls:0.21%
—
—
—
—
—
—
—
—
cases:4.07%
controls:0.57%
12
27
327
3363
8
7
331
3383
—
—
—
—
10
14
236
2463
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
6.4e-01
7.6e-01
1.9e+00
—
1.7e+00
8.5e-01
8.7e-01
cases:12.98%
controls:7.32%
cases:7.37%
controls:3.60%
cases:2.36%
controls:0.35%
—
—
cases:2.37%
controls:0.44%
cases:7.55%
controls:3.38%
cases:17.07%
controls:7.91%
44
248
295
3142
25
122
314
3268
8
12
331
3378
—
8
15
330
3364
24
109
294
3113
42
196
204
2281
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
1.1e+00
1.0e+00
1.1e+00
—
1.6e+00
1.1e+00
1.0e+00
cases:16.22%
controls:5.90%
cases:6.78%
controls:2.57%
cases:1.47%
controls:0.47%
—
—
cases:2.37%
controls:0.47%
cases:7.55%
controls:2.55%
cases:14.63%
controls:5.77%
55
200
284
3190
23
87
316
3303
5
16
334
3374
—
8
16
330
3363
24
82
294
3140
36
143
210
2334
Chronic ulcer skin
S97 [2002001061]
1.9e+00
2.0e+00
—
—
—
2.0e+00
1.3e+00
cases:2.65%
controls:0.41%
cases:1.77%
controls:0.24%
—
—
—
—
—
—
cases:2.83%
controls:0.40%
cases:3.25%
controls:0.89%
9
14
330
3376
6
8
333
3382
—
—
—
9
13
309
3209
8
22
238
2455
Bacteria identified in Isolate by Culture
43409-2 [3042936]
1.1e+00
2.1e+00
—
1.0e+50
—
1.4e+00
1.2e+00
cases:6.49%
controls:2.24%
cases:6.19%
controls:0.83%
—
—
cases:9.73%
controls:0.00%
—
—
cases:4.40%
controls:1.12%
cases:7.72%
controls:2.54%
22
76
317
3314
21
28
318
3362
—
33
0
306
3390
—
14
36
304
3186
19
63
227
2414
Inpatient Hospital
21 [8717]
6.6e-01
9.7e-01
4.2e-01
1.0e+50
2.3e+00
9.1e-01
8.6e-01
cases:36.87%
controls:23.16%
cases:17.11%
controls:7.26%
cases:1.47%
controls:0.97%
cases:13.57%
controls:0.00%
cases:6.51%
controls:0.68%
cases:15.72%
controls:7.01%
cases:35.37%
controls:18.81%
125
785
214
2605
58
246
281
3144
5
33
334
3357
46
0
293
3390
22
23
316
3356
50
226
268
2996
87
466
159
2011
codeine and paracetamol
N02AJ06 [1123647]
9.7e-01
9.5e-01
1.2e+00
—
1.7e+00
1.1e+00
9.6e-01
cases:25.66%
controls:11.53%
cases:10.03%
controls:4.13%
cases:2.06%
controls:0.65%
—
—
cases:2.96%
controls:0.56%
cases:11.64%
controls:4.22%
cases:21.14%
controls:9.29%
87
391
252
2999
34
140
305
3250
7
22
332
3368
—
10
19
328
3360
37
136
281
3086
52
230
194
2247
Gout, unspecified
M10.9 [45543454]
1.1e+00
1.7e+00
—
—
—
2.1e+00
1.9e+00
cases:2.65%
controls:0.91%
cases:2.95%
controls:0.53%
—
—
—
—
—
—
cases:3.77%
controls:0.50%
cases:5.69%
controls:0.93%
9
31
330
3359
10
18
329
3372
—
—
—
12
16
306
3206
14
23
232
2454
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
5.6e-01
7.1e-01
1.7e+00
—
1.6e+00
8.0e-01
8.3e-01
cases:15.34%
controls:9.41%
cases:8.26%
controls:4.25%
cases:2.65%
controls:0.47%
—
—
cases:2.96%
controls:0.59%
cases:7.55%
controls:3.54%
cases:17.89%
controls:8.64%
52
319
287
3071
28
144
311
3246
9
16
330
3374
—
10
20
328
3359
24
114
294
3108
44
214
202
2263
Hand Surgery
40 [38004480]
9.4e-01
2.1e+00
—
1.0e+50
—
2.1e+00
1.3e+00
cases:4.13%
controls:1.65%
cases:2.36%
controls:0.29%
—
—
cases:4.72%
controls:0.00%
—
—
cases:5.03%
controls:0.62%
cases:6.50%
controls:1.82%
14
56
325
3334
8
10
331
3380
—
16
0
323
3390
—
16
20
302
3202
16
45
230
2432
etoricoxib; oral
M01AH05 [21603996]
7.0e-01
1.1e+00
1.1e+00
—
2.0e+00
8.8e-01
9.1e-01
cases:21.24%
controls:11.80%
cases:12.09%
controls:4.37%
cases:2.36%
controls:0.80%
—
—
cases:2.66%
controls:0.38%
cases:10.69%
controls:4.75%
cases:23.98%
controls:11.22%
72
400
267
2990
41
148
298
3242
8
27
331
3363
—
9
13
329
3366
34
153
284
3069
59
278
187
2199
Other seropositive rheumatoid arthritis
M05.8 [45538634]
1.8e+00
1.4e+00
—
—
—
1.9e+00
1.8e+00
cases:3.83%
controls:0.68%
cases:2.65%
controls:0.65%
—
—
—
—
—
—
cases:3.77%
controls:0.56%
cases:4.88%
controls:0.81%
13
23
326
3367
9
22
330
3368
—
—
—
12
18
306
3204
12
20
234
2457
furosemide; oral, parenteral
C03CA01 [21601518]
7.9e-01
8.1e-01
1.1e+00
—
1.1e+00
9.3e-01
7.7e-01
cases:12.39%
controls:6.05%
cases:11.50%
controls:5.49%
cases:5.31%
controls:1.77%
—
—
cases:5.03%
controls:1.75%
cases:13.52%
controls:5.83%
cases:16.26%
controls:8.28%
42
205
297
3185
39
186
300
3204
18
60
321
3330
—
17
59
321
3320
43
188
275
3034
40
205
206
2272
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.6e-01
5.2e-01
1.6e+00
—
2.1e+00
6.6e-01
5.5e-01
cases:39.82%
controls:33.86%
cases:29.50%
controls:19.85%
cases:16.22%
controls:3.63%
—
—
cases:23.96%
controls:3.58%
cases:31.45%
controls:19.12%
cases:47.56%
controls:34.44%
135
1148
204
2242
100
673
239
2717
55
123
284
3267
—
81
121
257
3258
100
616
218
2606
117
853
129
1624
Home Visit
OMOP4822459 [581476]
6.0e-01
4.0e-01
1.1e+00
2.1e+00
1.7e+00
8.6e-01
7.0e-01
cases:8.55%
controls:4.90%
cases:4.13%
controls:2.80%
cases:2.65%
controls:0.94%
cases:2.06%
controls:0.27%
cases:4.73%
controls:0.86%
cases:8.18%
controls:3.63%
cases:15.04%
controls:8.11%
29
166
310
3224
14
95
325
3295
9
32
330
3358
7
9
332
3381
16
29
322
3350
26
117
292
3105
37
201
209
2276
Erysipelas
A46 [45561706]
1.3e+00
1.5e+00
—
1.0e+50
—
1.5e+00
1.1e+00
cases:6.49%
controls:1.80%
cases:2.95%
controls:0.68%
—
—
cases:3.83%
controls:0.00%
—
—
cases:3.14%
controls:0.74%
cases:6.91%
controls:2.50%
22
61
317
3329
10
23
329
3367
—
13
0
326
3390
—
10
24
308
3198
17
62
229
2415
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
1.4e+00
1.6e+00
—
—
—
1.4e+00
9.5e-01
cases:7.08%
controls:1.80%
cases:3.54%
controls:0.74%
—
—
—
—
—
—
cases:4.40%
controls:1.15%
cases:7.72%
controls:3.15%
24
61
315
3329
12
25
327
3365
—
—
—
14
37
304
3185
19
78
227
2399
gabapentin; oral
N02BF01 [955005]
1.1e+00
1.5e+00
1.6e+00
—
—
1.2e+00
1.5e+00
cases:5.01%
controls:1.71%
cases:4.72%
controls:1.09%
cases:1.47%
controls:0.29%
—
—
—
—
cases:3.77%
controls:1.12%
cases:9.76%
controls:2.42%
17
58
322
3332
16
37
323
3353
5
10
334
3380
—
—
12
36
306
3186
24
60
222
2417
Sampling
SPAT1263 [2001700364]
4.4e-01
9.7e-01
2.4e+00
—
1.8e+00
6.6e-01
5.1e-01
cases:12.68%
controls:8.55%
cases:7.37%
controls:2.92%
cases:3.83%
controls:0.35%
—
—
cases:3.25%
controls:0.53%
cases:5.66%
controls:3.01%
cases:11.38%
controls:7.15%
43
290
296
3100
25
99
314
3291
13
12
326
3378
—
11
18
327
3361
18
97
300
3125
28
177
218
2300
Hand/finger symptom/complaint
L12 [2002000636]
1.1e+00
2.5e+00
—
—
—
2.7e+00
4.8e-01
cases:3.54%
controls:1.24%
cases:2.36%
controls:0.21%
—
—
—
—
—
—
cases:2.83%
controls:0.19%
cases:2.85%
controls:1.78%
12
42
327
3348
8
7
331
3383
—
—
—
9
6
309
3216
7
44
239
2433
Arthrocentesis, unspecified region, unspecified region
TNX10 [2001308560]
2.0e+00
2.3e+00
—
—
—
—
3.0e+00
cases:2.95%
controls:0.41%
cases:1.47%
controls:0.15%
—
—
—
—
—
—
—
—
cases:4.88%
controls:0.24%
10
14
329
3376
5
5
334
3385
—
—
—
—
12
6
234
2471
Cathetrisation of vein
TPH04 [2001309597]
9.3e-01
1.4e+00
—
—
—
1.7e+00
1.1e+00
cases:7.67%
controls:3.19%
cases:3.24%
controls:0.86%
—
—
—
—
—
—
cases:4.40%
controls:0.87%
cases:6.91%
controls:2.46%
26
108
313
3282
11
29
328
3361
—
—
—
14
28
304
3194
17
61
229
2416
Physiotherapy
R4110 [2001310233]
1.1e+00
1.5e+00
—
—
—
1.5e+00
9.6e-01
cases:10.91%
controls:3.98%
cases:5.01%
controls:1.21%
—
—
—
—
—
—
cases:5.03%
controls:1.18%
cases:9.35%
controls:3.79%
37
135
302
3255
17
41
322
3349
—
—
—
16
38
302
3184
23
94
223
2383
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
5.2e-01
6.0e-01
9.1e-01
—
1.3e+00
7.6e-01
8.5e-01
cases:41.89%
controls:29.97%
cases:25.07%
controls:15.46%
cases:7.67%
controls:3.24%
—
—
cases:8.88%
controls:2.52%
cases:27.67%
controls:15.18%
cases:53.66%
controls:33.10%
142
1016
197
2374
85
524
254
2866
26
110
313
3280
—
30
85
308
3294
88
489
230
2733
132
820
114
1657
Pain in limb
M79.6 [45587063]
1.2e+00
1.4e+00
—
—
—
1.3e+00
1.0e+00
cases:10.91%
controls:3.57%
cases:5.60%
controls:1.39%
—
—
—
—
—
—
cases:5.66%
controls:1.68%
cases:12.60%
controls:4.88%
37
121
302
3269
19
47
320
3343
—
—
—
18
54
300
3168
31
121
215
2356
Rotator cuff syndrome
M75.1 [45596678]
1.5e+00
8.3e-01
—
—
—
1.7e+00
1.6e+00
cases:6.49%
controls:1.47%
cases:1.47%
controls:0.65%
—
—
—
—
—
—
cases:2.83%
controls:0.53%
cases:8.54%
controls:1.86%
22
50
317
3340
5
22
334
3368
—
—
—
9
17
309
3205
21
46
225
2431
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.9e-01
5.1e-01
9.2e-01
—
1.4e+00
7.5e-01
6.8e-01
cases:33.33%
controls:21.71%
cases:18.88%
controls:12.30%
cases:5.60%
controls:2.30%
—
—
cases:7.69%
controls:2.07%
cases:23.27%
controls:12.48%
cases:36.59%
controls:22.65%
113
736
226
2654
64
417
275
2973
19
78
320
3312
—
26
70
312
3309
74
402
244
2820
90
561
156
1916
Respiratory and circulatory monitoring
WX700 [2001310817]
1.2e+00
—
—
—
—
1.9e+00
1.7e+00
cases:7.08%
controls:2.24%
—
—
—
—
—
—
—
—
cases:2.20%
controls:0.34%
cases:6.50%
controls:1.25%
24
76
315
3314
—
—
—
—
7
11
311
3211
16
31
230
2446
Spinal stenosis
M48.0 [45557888]
1.4e+00
1.9e+00
—
1.0e+50
—
1.2e+00
1.3e+00
cases:4.72%
controls:1.15%
cases:3.54%
controls:0.53%
—
—
cases:1.47%
controls:0.00%
—
—
cases:2.52%
controls:0.78%
cases:5.28%
controls:1.45%
16
39
323
3351
12
18
327
3372
—
5
0
334
3390
—
8
25
310
3197
13
36
233
2441
Inpatient Visit
IP [9201]
6.5e-01
4.1e-01
—
1.0e+50
2.3e+00
1.0e+00
6.7e-01
cases:14.16%
controls:7.96%
cases:4.42%
controls:2.98%
—
—
cases:2.65%
controls:0.00%
cases:2.96%
controls:0.30%
cases:7.86%
controls:2.95%
cases:15.04%
controls:8.32%
48
270
291
3120
15
101
324
3289
—
9
0
330
3390
10
10
328
3369
25
95
293
3127
37
206
209
2271
Asthma
R96 [2002000961]
1.3e+00
1.4e+00
—
—
—
1.8e+00
1.6e+00
cases:3.83%
controls:1.12%
cases:1.47%
controls:0.35%
—
—
—
—
—
—
cases:2.52%
controls:0.43%
cases:4.88%
controls:1.01%
13
38
326
3352
5
12
334
3378
—
—
—
8
14
310
3208
12
25
234
2452
Limited function/disability NOS
A28 [2002000162]
9.3e-01
1.3e+00
1.5e+00
—
1.9e+00
1.4e+00
9.4e-02
cases:4.72%
controls:1.92%
cases:4.13%
controls:1.15%
cases:1.77%
controls:0.38%
—
—
cases:2.96%
controls:0.44%
cases:5.66%
controls:1.52%
cases:4.07%
controls:3.71%
16
65
323
3325
14
39
325
3351
6
13
333
3377
—
10
15
328
3364
18
49
300
3173
10
92
236
2385
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
1.3e+00
1.9e+00
—
—
—
1.3e+00
1.4e+00
cases:3.54%
controls:1.03%
cases:3.83%
controls:0.59%
—
—
—
—
—
—
cases:2.52%
controls:0.68%
cases:6.91%
controls:1.86%
12
35
327
3355
13
20
326
3370
—
—
—
8
22
310
3200
17
46
229
2431
hydroxychloroquine; oral
P01BA02 [21604889]
1.5e+00
1.5e+00
—
—
—
1.5e+00
1.2e+00
cases:3.54%
controls:0.83%
cases:2.65%
controls:0.62%
—
—
—
—
—
—
cases:2.83%
controls:0.65%
cases:2.85%
controls:0.89%
12
28
327
3362
9
21
330
3369
—
—
—
9
21
309
3201
7
22
239
2455
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
5.1e-01
4.8e-01
1.4e+00
—
1.8e+00
5.8e-01
6.4e-01
cases:28.91%
controls:19.62%
cases:14.45%
controls:9.50%
cases:5.01%
controls:1.27%
—
—
cases:6.21%
controls:1.07%
cases:14.15%
controls:8.47%
cases:32.52%
controls:20.23%
98
665
241
2725
49
322
290
3068
17
43
322
3347
—
21
36
317
3343
45
273
273
2949
80
501
166
1976
amitriptyline; oral, parenteral
N06AA09 [21604696]
1.1e+00
1.5e+00
—
—
1.8e+00
1.2e+00
7.8e-01
cases:8.26%
controls:2.95%
cases:3.83%
controls:0.88%
—
—
—
—
cases:2.07%
controls:0.36%
cases:3.46%
controls:1.06%
cases:4.47%
controls:2.10%
28
100
311
3290
13
30
326
3360
—
—
7
12
331
3367
11
34
307
3188
11
52
235
2425
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
1.4e+00
1.5e+00
—
—
—
1.3e+00
8.6e-01
cases:6.78%
controls:1.71%
cases:3.54%
controls:0.83%
—
—
—
—
—
—
cases:4.72%
controls:1.37%
cases:7.72%
controls:3.43%
23
58
316
3332
12
28
327
3362
—
—
—
15
44
303
3178
19
85
227
2392
Internal Medicine
11 [38004456]
6.3e-01
6.6e-01
7.0e-01
—
1.4e+00
7.3e-01
7.1e-01
cases:31.56%
controls:19.65%
cases:12.98%
controls:7.17%
cases:2.36%
controls:1.18%
—
—
cases:4.44%
controls:1.12%
cases:13.84%
controls:7.17%
cases:30.49%
controls:17.76%
107
666
232
2724
44
243
295
3147
8
40
331
3350
—
15
38
323
3341
44
231
274
2991
75
440
171
2037
allopurinol; oral, parenteral
M04AA01 [21604131]
8.8e-01
8.6e-01
1.4e+00
—
1.1e+00
1.2e+00
1.2e+00
cases:7.96%
controls:3.45%
cases:6.19%
controls:2.71%
cases:2.06%
controls:0.50%
—
—
cases:2.66%
controls:0.92%
cases:8.81%
controls:2.76%
cases:10.98%
controls:3.75%
27
117
312
3273
21
92
318
3298
7
17
332
3373
—
9
31
329
3348
28
89
290
3133
27
93
219
2384
Neurosurgery
14 [38004459]
1.3e+00
1.5e+00
—
—
-1.0e+50
1.3e+00
1.3e+00
cases:5.31%
controls:1.56%
cases:2.65%
controls:0.59%
—
—
—
—
cases:0.00%
controls:0.24%
cases:2.20%
controls:0.59%
cases:6.10%
controls:1.70%
18
53
321
3337
9
20
330
3370
—
—
0
8
338
3371
7
19
311
3203
15
42
231
2435
Fractional oxyhemoglobin in Venous blood
2716-9 [3019230]
1.8e+00
—
—
—
—
2.3e+00
—
cases:2.06%
controls:0.35%
—
—
—
—
—
—
—
—
cases:1.57%
controls:0.16%
—
—
7
12
332
3378
—
—
—
—
5
5
313
3217
—
Bacteria identified in Urine by Culture
630-4 [3026008]
2.5e-01
9.0e-01
—
—
2.5e+00
6.8e-01
7.2e-01
cases:7.37%
controls:5.84%
cases:6.19%
controls:2.63%
—
—
—
—
cases:2.37%
controls:0.21%
cases:5.66%
controls:2.95%
cases:12.20%
controls:6.34%
25
198
314
3192
21
89
318
3301
—
—
8
7
330
3372
18
95
300
3127
30
157
216
2320
Limited function/disability (L)
L28 [2002000647]
1.2e+00
1.5e+00
—
—
—
1.4e+00
8.9e-01
cases:5.60%
controls:1.83%
cases:2.95%
controls:0.68%
—
—
—
—
—
—
cases:4.09%
controls:1.02%
cases:6.50%
controls:2.79%
19
62
320
3328
10
23
329
3367
—
—
—
13
33
305
3189
16
69
230
2408
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
7.5e-01
1.2e+00
1.9e+00
—
2.6e+00
1.3e+00
1.5e+00
cases:3.54%
controls:1.71%
cases:2.06%
controls:0.65%
cases:1.77%
controls:0.27%
—
—
cases:2.66%
controls:0.21%
cases:2.83%
controls:0.78%
cases:6.50%
controls:1.57%
12
58
327
3332
7
22
332
3368
6
9
333
3381
—
9
7
329
3372
9
25
309
3197
16
39
230
2438
Foot/toe symptom/complaint
L17 [2002000641]
9.5e-01
1.1e+00
—
—
-1.0e+50
1.1e+00
8.3e-01
cases:8.85%
controls:3.63%
cases:4.13%
controls:1.42%
—
—
—
—
cases:0.00%
controls:0.21%
cases:4.09%
controls:1.37%
cases:10.16%
controls:4.68%
30
123
309
3267
14
48
325
3342
—
—
0
7
338
3372
13
44
305
3178
25
116
221
2361
Gas panel - Venous blood
24339-4 [3000991]
1.3e+00
1.4e+00
—
—
—
1.5e+00
1.2e+00
cases:5.01%
controls:1.42%
cases:2.36%
controls:0.59%
—
—
—
—
—
—
cases:3.46%
controls:0.81%
cases:6.10%
controls:1.94%
17
48
322
3342
8
20
331
3370
—
—
—
11
26
307
3196
15
48
231
2429
Supplier / Service Provider
OMOP5117446 [33004]
-2.8e-01
4.3e-03
—
—
—
1.7e+00
2.2e+00
cases:23.01%
controls:28.44%
cases:7.37%
controls:7.35%
—
—
—
—
—
—
cases:3.77%
controls:0.71%
cases:11.38%
controls:1.41%
78
964
261
2426
25
249
314
3141
—
—
—
12
23
306
3199
28
35
218
2442
pantoprazole; oral, parenteral
A02BC02 [21600097]
6.9e-01
6.7e-01
7.2e-01
—
1.1e+00
8.0e-01
5.9e-01
cases:28.32%
controls:16.52%
cases:16.81%
controls:9.41%
cases:4.72%
controls:2.36%
—
—
cases:5.92%
controls:2.13%
cases:18.87%
controls:9.50%
cases:27.64%
controls:17.44%
96
560
243
2830
57
319
282
3071
16
80
323
3310
—
20
72
318
3307
60
306
258
2916
68
432
178
2045
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
1.1e+00
1.3e+00
1.8e+00
—
—
1.3e+00
6.9e-01
cases:10.03%
controls:3.48%
cases:4.13%
controls:1.12%
cases:1.47%
controls:0.24%
—
—
—
—
cases:4.40%
controls:1.24%
cases:9.35%
controls:4.93%
34
118
305
3272
14
38
325
3352
5
8
334
3382
—
—
14
40
304
3182
23
122
223
2355
Physical Medicine And Rehabilitation
25 [38004468]
1.1e+00
1.1e+00
—
1.0e+50
2.0e+00
1.0e+00
1.5e+00
cases:11.80%
controls:4.28%
cases:4.42%
controls:1.50%
—
—
cases:1.47%
controls:0.00%
cases:1.48%
controls:0.21%
cases:4.40%
controls:1.61%
cases:13.82%
controls:3.35%
40
145
299
3245
15
51
324
3339
—
5
0
334
3390
5
7
333
3372
14
52
304
3170
34
83
212
2394
Differential panel, method unspecified - Blood
69738-3 [42870588]
1.0e+00
1.1e+00
1.2e+00
—
1.1e+00
8.5e-01
7.4e-01
cases:20.35%
controls:8.29%
cases:12.98%
controls:4.90%
cases:2.95%
controls:0.88%
—
—
cases:3.25%
controls:1.12%
cases:10.69%
controls:4.87%
cases:15.85%
controls:8.28%
69
281
270
3109
44
166
295
3224
10
30
329
3360
—
11
38
327
3341
34
157
284
3065
39
205
207
2272
Other specified counselling
Z71.8 [45581061]
7.4e-01
1.0e+00
—
—
—
9.6e-01
9.4e-01
cases:8.55%
controls:4.28%
cases:6.19%
controls:2.30%
—
—
—
—
—
—
cases:6.92%
controls:2.76%
cases:14.63%
controls:6.30%
29
145
310
3245
21
78
318
3312
—
—
—
22
89
296
3133
36
156
210
2321
Standard cardiac ultrasound examination
FM1AE [2001303278]
9.7e-01
1.1e+00
—
—
—
1.5e+00
7.3e-01
cases:7.96%
controls:3.19%
cases:3.83%
controls:1.27%
—
—
—
—
—
—
cases:4.72%
controls:1.06%
cases:5.69%
controls:2.83%
27
108
312
3282
13
43
326
3347
—
—
—
15
34
303
3188
14
70
232
2407
Major dressing of wound of skin of lower limb
QDB10 [2001309970]
1.9e+00
—
—
—
—
—
1.7e+00
cases:2.95%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:0.61%
10
16
329
3374
—
—
—
—
—
8
15
238
2462
Pain in joint
M25.5 [45586941]
1.0e+00
1.4e+00
—
—
—
1.0e+00
9.6e-01
cases:9.14%
controls:3.51%
cases:4.13%
controls:1.09%
—
—
—
—
—
—
cases:3.14%
controls:1.15%
cases:8.13%
controls:3.27%
31
119
308
3271
14
37
325
3353
—
—
—
10
37
308
3185
20
81
226
2396
Office Visit
OMOP4822458 [581477]
9.5e-01
1.3e+00
—
—
—
9.7e-01
1.1e+00
cases:13.27%
controls:5.60%
cases:4.72%
controls:1.36%
—
—
—
—
—
—
cases:3.77%
controls:1.46%
cases:12.20%
controls:4.52%
45
190
294
3200
16
46
323
3344
—
—
—
12
47
306
3175
30
112
216
2365
Outpatient Hospital
22 [8756]
6.2e-01
8.8e-01
—
1.0e+50
—
9.8e-01
7.6e-01
cases:29.20%
controls:18.23%
cases:10.32%
controls:4.54%
—
—
cases:4.42%
controls:0.00%
—
—
cases:11.32%
controls:4.59%
cases:24.39%
controls:13.12%
99
618
240
2772
35
154
304
3236
—
15
0
324
3390
—
36
148
282
3074
60
325
186
2152
Leukocytes [#/volume] in Synovial fluid
26469-7 [3000475]
—
3.2e+00
1.0e+50
1.0e+50
—
—
1.4e+00
—
—
cases:3.54%
controls:0.15%
cases:1.77%
controls:0.00%
cases:2.65%
controls:0.00%
—
—
—
—
cases:2.03%
controls:0.48%
—
12
5
327
3385
6
0
333
3390
9
0
330
3390
—
—
5
12
241
2465
desloratadine; oral
R06AX27 [21603526]
4.1e-01
1.2e+00
2.0e+00
—
—
9.4e-01
6.8e-01
cases:5.31%
controls:3.60%
cases:5.60%
controls:1.80%
cases:1.77%
controls:0.24%
—
—
—
—
cases:4.40%
controls:1.77%
cases:7.32%
controls:3.84%
18
122
321
3268
19
61
320
3329
6
8
333
3382
—
—
14
57
304
3165
18
95
228
2382
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
4.7e-01
7.2e-01
1.6e+00
1.0e+50
9.2e-01
9.0e-01
6.8e-01
cases:14.75%
controls:9.73%
cases:7.37%
controls:3.75%
cases:2.36%
controls:0.47%
cases:1.47%
controls:0.00%
cases:1.48%
controls:0.59%
cases:8.81%
controls:3.79%
cases:17.07%
controls:9.49%
50
330
289
3060
25
127
314
3263
8
16
331
3374
5
0
334
3390
5
20
333
3359
28
122
290
3100
42
235
204
2242
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
5.3e-01
4.4e-01
1.3e+00
—
9.9e-01
6.2e-01
7.1e-01
cases:27.14%
controls:18.05%
cases:12.39%
controls:8.38%
cases:3.24%
controls:0.88%
—
—
cases:2.96%
controls:1.12%
cases:13.84%
controls:7.98%
cases:28.86%
controls:16.59%
92
612
247
2778
42
284
297
3106
11
30
328
3360
—
10
38
328
3341
44
257
274
2965
71
411
175
2066
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
6.4e-01
1.8e+00
—
—
—
1.1e+00
1.3e+00
cases:4.42%
controls:2.39%
cases:3.83%
controls:0.65%
—
—
—
—
—
—
cases:2.20%
controls:0.74%
cases:7.72%
controls:2.22%
15
81
324
3309
13
22
326
3368
—
—
—
7
24
311
3198
19
55
227
2422
clindamycin; oral, parenteral
J01FF01 [21602985]
1.3e+00
1.3e+00
—
1.0e+50
—
1.9e+00
6.9e-01
cases:7.96%
controls:2.42%
cases:2.95%
controls:0.83%
—
—
cases:1.77%
controls:0.00%
—
—
cases:4.40%
controls:0.71%
cases:5.69%
controls:2.95%
27
82
312
3308
10
28
329
3362
—
6
0
333
3390
—
14
23
304
3199
14
73
232
2404
Skin texture symptom/complaint
S21 [2002000986]
9.6e-01
1.9e+00
—
—
—
1.3e+00
1.2e+00
cases:4.72%
controls:1.86%
cases:2.65%
controls:0.41%
—
—
—
—
—
—
cases:2.20%
controls:0.59%
cases:5.69%
controls:1.82%
16
63
323
3327
9
14
330
3376
—
—
—
7
19
311
3203
14
45
232
2432
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
1.3e+00
1.2e+00
-1.0e+50
—
—
1.7e+00
9.7e-01
cases:3.83%
controls:1.03%
cases:1.77%
controls:0.53%
cases:0.00%
controls:0.18%
—
—
—
—
cases:2.52%
controls:0.47%
cases:3.25%
controls:1.25%
13
35
326
3355
6
18
333
3372
0
6
339
3384
—
—
8
15
310
3207
8
31
238
2446
celecoxib; oral
M01AH01 [21603992]
1.4e+00
—
—
—
—
1.9e+00
1.6e+00
cases:4.13%
controls:1.00%
—
—
—
—
—
—
—
—
cases:1.57%
controls:0.25%
cases:5.69%
controls:1.21%
14
34
325
3356
—
—
—
—
5
8
313
3214
14
30
232
2447
celecoxib
L01XX33 [21603805]
1.4e+00
—
—
—
—
1.9e+00
1.6e+00
cases:4.13%
controls:1.00%
—
—
—
—
—
—
—
—
cases:1.57%
controls:0.25%
cases:5.69%
controls:1.21%
14
34
325
3356
—
—
—
—
5
8
313
3214
14
30
232
2447
Cell count panel - Synovial fluid
34559-5 [3044941]
—
3.0e+00
1.0e+50
1.0e+50
—
—
—
—
—
cases:2.95%
controls:0.15%
cases:1.77%
controls:0.00%
cases:2.36%
controls:0.00%
—
—
—
—
—
—
—
10
5
329
3385
6
0
333
3390
8
0
331
3390
—
—
—
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
5.1e-01
5.4e-01
6.2e-01
—
1.7e+00
5.8e-01
7.6e-01
cases:18.88%
controls:12.21%
cases:9.73%
controls:5.90%
cases:2.65%
controls:1.45%
—
—
cases:5.03%
controls:0.92%
cases:11.32%
controls:6.64%
cases:24.80%
controls:13.32%
64
414
275
2976
33
200
306
3190
9
49
330
3341
—
17
31
321
3348
36
214
282
3008
61
330
185
2147
Eosinophils [#/volume] in Blood
26449-9 [3013115]
7.6e-01
9.1e-01
8.6e-01
—
8.6e-01
7.4e-01
5.8e-01
cases:23.60%
controls:12.65%
cases:17.11%
controls:7.64%
cases:3.54%
controls:1.53%
—
—
cases:3.85%
controls:1.66%
cases:13.52%
controls:6.95%
cases:23.17%
controls:14.49%
80
429
259
2961
58
259
281
3131
12
52
327
3338
—
13
56
325
3323
43
224
275
2998
57
359
189
2118
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
8.2e-01
1.0e+00
—
—
—
1.2e+00
4.2e-01
cases:6.49%
controls:2.98%
cases:4.72%
controls:1.77%
—
—
—
—
—
—
cases:5.03%
controls:1.64%
cases:5.28%
controls:3.55%
22
101
317
3289
16
60
323
3330
—
—
—
16
53
302
3169
13
88
233
2389
Monocytes [#/volume] in Blood
26484-6 [3001604]
8.1e-01
9.1e-01
9.2e-01
—
9.8e-01
7.0e-01
5.5e-01
cases:23.89%
controls:12.30%
cases:16.52%
controls:7.37%
cases:3.54%
controls:1.45%
—
—
cases:4.14%
controls:1.60%
cases:12.89%
controls:6.83%
cases:22.36%
controls:14.21%
81
417
258
2973
56
250
283
3140
12
49
327
3341
—
14
54
324
3325
41
220
277
3002
55
352
191
2125
Fungus identified in Specimen by Culture
580-1 [3000494]
9.9e-01
9.8e-01
—
—
—
1.9e+00
6.4e-01
cases:5.90%
controls:2.27%
cases:1.47%
controls:0.56%
—
—
—
—
—
—
cases:4.09%
controls:0.62%
cases:4.88%
controls:2.62%
20
77
319
3313
5
19
334
3371
—
—
—
13
20
305
3202
12
65
234
2412
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
4.5e-01
3.8e-01
1.1e+00
—
1.4e+00
7.4e-01
7.2e-01
cases:23.89%
controls:16.73%
cases:11.21%
controls:7.96%
cases:2.65%
controls:0.94%
—
—
cases:4.14%
controls:1.01%
cases:13.84%
controls:7.11%
cases:26.83%
controls:15.10%
81
567
258
2823
38
270
301
3120
9
32
330
3358
—
14
34
324
3345
44
229
274
2993
66
374
180
2103
No disease
A97 [2002000230]
6.7e-01
1.5e+00
—
—
—
1.4e+00
1.7e-01
cases:4.13%
controls:2.15%
cases:3.83%
controls:0.91%
—
—
—
—
—
—
cases:3.77%
controls:0.96%
cases:3.66%
controls:3.11%
14
73
325
3317
13
31
326
3359
—
—
—
12
31
306
3191
9
77
237
2400
Basophils/Leukocytes in Blood
30180-4 [3022096]
7.5e-01
8.8e-01
9.8e-01
—
9.4e-01
6.5e-01
5.7e-01
cases:21.83%
controls:11.68%
cases:15.04%
controls:6.87%
cases:3.54%
controls:1.36%
—
—
cases:3.85%
controls:1.54%
cases:11.64%
controls:6.42%
cases:20.73%
controls:12.84%
74
396
265
2994
51
233
288
3157
12
46
327
3344
—
13
52
325
3327
37
207
281
3015
51
318
195
2159
Monocytes/Leukocytes in Blood
26485-3 [3019069]
7.6e-01
8.5e-01
9.8e-01
—
9.4e-01
6.5e-01
5.7e-01
cases:22.12%
controls:11.74%
cases:14.75%
controls:6.87%
cases:3.54%
controls:1.36%
—
—
cases:3.85%
controls:1.54%
cases:11.64%
controls:6.46%
cases:20.73%
controls:12.88%
75
398
264
2992
50
233
289
3157
12
46
327
3344
—
13
52
325
3327
37
208
281
3014
51
319
195
2158
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
7.4e-01
8.6e-01
9.8e-01
—
9.4e-01
6.5e-01
5.7e-01
cases:21.83%
controls:11.74%
cases:14.75%
controls:6.84%
cases:3.54%
controls:1.36%
—
—
cases:3.85%
controls:1.54%
cases:11.64%
controls:6.46%
cases:20.73%
controls:12.88%
74
398
265
2992
50
232
289
3158
12
46
327
3344
—
13
52
325
3327
37
208
281
3014
51
319
195
2158
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
3.7e-01
4.3e-01
1.5e+00
—
7.6e-01
6.5e-01
6.2e-01
cases:20.65%
controls:15.28%
cases:10.62%
controls:7.20%
cases:4.13%
controls:0.91%
—
—
cases:2.07%
controls:0.98%
cases:11.95%
controls:6.61%
cases:25.61%
controls:15.66%
70
518
269
2872
36
244
303
3146
14
31
325
3359
—
7
33
331
3346
38
213
280
3009
63
388
183
2089
salbutamol; inhalant
R03AC02 [21603256]
5.7e-01
7.6e-01
1.0e+00
—
3.3e-01
7.9e-01
6.7e-01
cases:18.88%
controls:11.65%
cases:11.80%
controls:5.87%
cases:3.24%
controls:1.21%
—
—
cases:1.48%
controls:1.07%
cases:11.64%
controls:5.65%
cases:21.54%
controls:12.35%
64
395
275
2995
40
199
299
3191
11
41
328
3349
—
5
36
333
3343
37
182
281
3040
53
306
193
2171
Other primary gonarthrosis
M17.1 [45596493]
7.9e-01
1.4e+00
—
—
—
8.2e-01
1.3e+00
cases:5.31%
controls:2.48%
cases:3.24%
controls:0.80%
—
—
—
—
—
—
cases:1.89%
controls:0.84%
cases:7.72%
controls:2.18%
18
84
321
3306
11
27
328
3363
—
—
—
6
27
312
3195
19
54
227
2423
General Practice Dentistry
1223G0001X [38003675]
2.7e+00
—
—
—
—
—
—
cases:2.65%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
9
6
330
3384
—
—
—
—
—
—
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
7.9e-01
1.5e+00
—
—
—
7.9e-01
1.2e+00
cases:5.60%
controls:2.63%
cases:2.95%
controls:0.68%
—
—
—
—
—
—
cases:1.89%
controls:0.87%
cases:7.72%
controls:2.38%
19
89
320
3301
10
23
329
3367
—
—
—
6
28
312
3194
19
59
227
2418
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
7.3e-01
7.5e-01
1.7e+00
—
1.7e+00
9.6e-01
1.0e+00
cases:12.39%
controls:6.37%
cases:6.49%
controls:3.19%
cases:2.06%
controls:0.38%
—
—
cases:2.07%
controls:0.38%
cases:6.92%
controls:2.76%
cases:15.85%
controls:6.34%
42
216
297
3174
22
108
317
3282
7
13
332
3377
—
7
13
331
3366
22
89
296
3133
39
157
207
2320
Crystals [Presence] in Synovial fluid by Light microscopy
38458-6 [3050238]
1.3e+00
2.6e+00
—
1.0e+50
—
—
1.3e+00
cases:1.47%
controls:0.41%
cases:2.36%
controls:0.18%
—
—
cases:2.06%
controls:0.00%
—
—
—
—
cases:2.44%
controls:0.65%
5
14
334
3376
8
6
331
3384
—
7
0
332
3390
—
—
6
16
240
2461
Essential (primary) hypertension
I10 [45591453]
3.6e-01
5.7e-01
6.3e-01
—
1.5e+00
4.8e-01
5.0e-01
cases:25.37%
controls:19.12%
cases:15.34%
controls:9.29%
cases:2.95%
controls:1.59%
—
—
cases:6.51%
controls:1.48%
cases:16.67%
controls:11.02%
cases:33.74%
controls:23.58%
86
648
253
2742
52
315
287
3075
10
54
329
3336
—
22
50
316
3329
53
355
265
2867
83
584
163
1893
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
9.9e-01
1.3e+00
—
—
—
1.6e+00
9.7e-01
cases:5.01%
controls:1.92%
cases:2.95%
controls:0.83%
—
—
—
—
—
—
cases:3.14%
controls:0.65%
cases:4.47%
controls:1.74%
17
65
322
3325
10
28
329
3362
—
—
—
10
21
308
3201
11
43
235
2434
leflunomide; oral
L04AK01 [955035]
2.5e+00
—
—
—
—
—
—
cases:1.77%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
333
3385
—
—
—
—
—
—
Infectious Disease
44 [38004484]
7.8e-01
1.2e+00
—
—
2.5e+00
1.3e+00
9.7e-01
cases:3.54%
controls:1.65%
cases:2.06%
controls:0.65%
—
—
—
—
cases:1.78%
controls:0.15%
cases:2.52%
controls:0.71%
cases:4.07%
controls:1.57%
12
56
327
3334
7
22
332
3368
—
—
6
5
332
3374
8
23
310
3199
10
39
236
2438
Hallux valgus (acquired)
M20.1 [45606152]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.85%
controls:0.24%
—
—
—
—
—
—
7
6
239
2471
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
7.1e-01
6.2e-01
—
—
—
9.9e-01
7.9e-01
cases:14.75%
controls:7.85%
cases:5.60%
controls:3.10%
—
—
—
—
—
—
cases:7.86%
controls:3.07%
cases:15.04%
controls:7.47%
50
266
289
3124
19
105
320
3285
—
—
—
25
99
293
3123
37
185
209
2292
One hour or less
ZXE00 [2001311394]
8.7e-01
—
—
—
—
1.0e+00
1.6e+00
cases:10.62%
controls:4.72%
—
—
—
—
—
—
—
—
cases:2.52%
controls:0.90%
cases:12.60%
controls:2.83%
36
160
303
3230
—
—
—
—
8
29
310
3193
31
70
215
2407
Seronegative rheumatoid arthritis
M06.0 [45577103]
2.5e+00
—
—
—
—
—
—
cases:2.36%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
8
7
331
3383
—
—
—
—
—
—
pH of Serum or Plasma
2753-2 [3018418]
4.2e-01
7.7e-01
6.6e-01
—
1.7e+00
5.3e-01
5.0e-01
cases:10.03%
controls:6.84%
cases:7.37%
controls:3.57%
cases:1.47%
controls:0.77%
—
—
cases:2.66%
controls:0.50%
cases:5.66%
controls:3.41%
cases:11.38%
controls:7.23%
34
232
305
3158
25
121
314
3269
5
26
334
3364
—
9
17
329
3362
18
110
300
3112
28
179
218
2298
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
4.9e-01
4.3e-01
1.8e+00
—
—
4.6e-01
6.6e-01
cases:15.34%
controls:10.00%
cases:7.96%
controls:5.31%
cases:2.06%
controls:0.35%
—
—
—
—
cases:7.55%
controls:4.90%
cases:21.95%
controls:12.68%
52
339
287
3051
27
180
312
3210
7
12
332
3378
—
—
24
158
294
3064
54
314
192
2163
Base excess in Venous blood by calculation
1927-3 [3002032]
8.2e-01
8.6e-01
—
—
—
1.4e+00
1.0e+00
cases:4.42%
controls:2.01%
cases:2.06%
controls:0.88%
—
—
—
—
—
—
cases:3.77%
controls:0.93%
cases:6.50%
controls:2.50%
15
68
324
3322
7
30
332
3360
—
—
—
12
30
306
3192
16
62
230
2415
Basophils [#/volume] in Blood
26444-0 [3006315]
7.8e-01
9.1e-01
9.2e-01
—
9.6e-01
7.0e-01
5.2e-01
cases:23.60%
controls:12.36%
cases:16.52%
controls:7.37%
cases:3.54%
controls:1.45%
—
—
cases:4.14%
controls:1.63%
cases:12.89%
controls:6.83%
cases:21.95%
controls:14.29%
80
419
259
2971
56
250
283
3140
12
49
327
3341
—
14
55
324
3324
41
220
277
3002
54
354
192
2123
potassium chloride; oral
A12BA01 [21600877]
1.2e+00
1.2e+00
1.4e+00
—
1.5e+00
1.0e+00
1.1e+00
cases:5.60%
controls:1.68%
cases:3.24%
controls:1.00%
cases:1.47%
controls:0.35%
—
—
cases:1.48%
controls:0.33%
cases:3.14%
controls:1.18%
cases:7.72%
controls:2.58%
19
57
320
3333
11
34
328
3356
5
12
334
3378
—
5
11
333
3368
10
38
308
3184
19
64
227
2413
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
7.6e-01
9.3e-01
9.0e-01
—
9.2e-01
6.6e-01
5.2e-01
cases:24.19%
controls:12.98%
cases:17.11%
controls:7.55%
cases:3.54%
controls:1.47%
—
—
cases:4.14%
controls:1.69%
cases:12.89%
controls:7.11%
cases:22.36%
controls:14.57%
82
440
257
2950
58
256
281
3134
12
50
327
3340
—
14
57
324
3322
41
229
277
2993
55
361
191
2116
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
1.5e+00
—
—
—
—
—
2.3e+00
cases:2.36%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
cases:4.07%
controls:0.40%
8
19
331
3371
—
—
—
—
—
10
10
236
2467
Oxygen saturation in Venous blood
2711-0 [3024928]
1.6e+00
—
—
—
—
2.3e+00
—
cases:2.06%
controls:0.41%
—
—
—
—
—
—
—
—
cases:1.89%
controls:0.19%
—
—
7
14
332
3376
—
—
—
—
6
6
312
3216
—
Skin infection other
S76 [2002001040]
1.3e+00
—
—
—
—
—
2.3e+00
cases:2.06%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
cases:2.44%
controls:0.24%
7
20
332
3370
—
—
—
—
—
6
6
240
2471
triamcinolone and antiinfectives
S02CA04 [21605176]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.03%
controls:0.20%
—
—
—
—
—
—
5
5
241
2472
GD
GD1LA [2001303643]
2.3e+00
—
—
—
—
—
—
cases:2.06%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
7
7
332
3383
—
—
—
—
—
—
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
281 [2001600213]
2.3e+00
—
—
—
—
—
—
cases:2.06%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
7
7
332
3383
—
—
—
—
—
—
Overall medication plan or its review
SPAT1252 [2001700353]
8.5e-01
2.3e+00
—
—
—
—
—
cases:1.77%
controls:0.77%
cases:1.77%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
6
26
333
3364
6
6
333
3384
—
—
—
—
—
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
7.7e-01
1.3e+00
-1.0e+50
—
—
1.2e+00
1.0e+00
cases:7.08%
controls:3.42%
cases:4.42%
controls:1.30%
cases:0.00%
controls:0.18%
—
—
—
—
cases:3.14%
controls:0.96%
cases:7.72%
controls:2.91%
24
116
315
3274
15
44
324
3346
0
6
339
3384
—
—
10
31
308
3191
19
72
227
2405
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
6.6e-01
8.7e-01
—
—
—
7.9e-01
7.5e-01
cases:10.32%
controls:5.63%
cases:6.49%
controls:2.83%
—
—
—
—
—
—
cases:5.97%
controls:2.79%
cases:12.60%
controls:6.38%
35
191
304
3199
22
96
317
3294
—
—
—
19
90
299
3132
31
158
215
2319
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
1.1e+00
1.1e+00
—
—
—
1.1e+00
5.6e-01
cases:7.37%
controls:2.51%
cases:3.54%
controls:1.21%
—
—
—
—
—
—
cases:5.03%
controls:1.71%
cases:8.13%
controls:4.80%
25
85
314
3305
12
41
327
3349
—
—
—
16
55
302
3167
20
119
226
2358
hydrocortisone
S02BA01 [21605166]
3.7e-01
-1.2e-01
—
—
-1.0e+50
1.4e+00
8.7e-01
cases:7.96%
controls:5.63%
cases:1.47%
controls:1.65%
—
—
—
—
cases:0.00%
controls:0.21%
cases:5.66%
controls:1.49%
cases:10.98%
controls:4.93%
27
191
312
3199
5
56
334
3334
—
—
0
7
338
3372
18
48
300
3174
27
122
219
2355
Carpal tunnel syndrome
G56.0 [45566891]
4.8e-01
2.2e+00
—
—
—
—
8.2e-01
cases:1.47%
controls:0.91%
cases:2.06%
controls:0.24%
—
—
—
—
—
—
—
—
cases:2.44%
controls:1.09%
5
31
334
3359
7
8
332
3382
—
—
—
—
6
27
240
2450
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
6.2e-01
8.5e-01
1.4e+00
—
1.0e+00
7.0e-01
5.4e-01
cases:15.63%
controls:9.03%
cases:11.21%
controls:5.10%
cases:2.65%
controls:0.68%
—
—
cases:1.48%
controls:0.53%
cases:9.43%
controls:4.90%
cases:17.89%
controls:11.30%
53
306
286
3084
38
173
301
3217
9
23
330
3367
—
5
18
333
3361
30
158
288
3064
44
280
202
2197
montelukast; oral
R03DC03 [21603356]
1.0e+00
1.2e+00
—
—
—
6.8e-01
6.1e-01
cases:5.90%
controls:2.24%
cases:4.42%
controls:1.42%
—
—
—
—
—
—
cases:2.83%
controls:1.46%
cases:4.88%
controls:2.70%
20
76
319
3314
15
48
324
3342
—
—
—
9
47
309
3175
12
67
234
2410
sotalol; oral, parenteral
C07AA07 [21601672]
2.2e+00
—
—
—
—
—
—
cases:1.77%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
333
3383
—
—
—
—
—
—
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
5.5e-01
4.8e-01
2.2e+00
—
—
-9.7e-02
4.4e-01
cases:6.49%
controls:3.83%
cases:4.42%
controls:2.77%
cases:1.77%
controls:0.21%
—
—
—
—
cases:2.20%
controls:2.42%
cases:11.38%
controls:7.63%
22
130
317
3260
15
94
324
3296
6
7
333
3383
—
—
7
78
311
3144
28
189
218
2288
Polymyalgia rheumatica
M35.3 [45533830]
1.6e+00
2.2e+00
—
—
—
1.9e+00
1.5e+00
cases:2.06%
controls:0.44%
cases:1.77%
controls:0.21%
—
—
—
—
—
—
cases:1.57%
controls:0.25%
cases:2.03%
controls:0.44%
7
15
332
3375
6
7
333
3383
—
—
—
5
8
313
3214
5
11
241
2466
ciclosporin; oral, parenteral
L04AD01 [21603924]
2.2e+00
—
—
—
—
—
—
cases:1.77%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
333
3383
—
—
—
—
—
—
Acute bronchitis, unspecified
J20.9 [45562445]
1.0e+00
—
—
—
—
—
1.1e+00
cases:4.72%
controls:1.74%
—
—
—
—
—
—
—
—
—
—
cases:5.28%
controls:1.82%
16
59
323
3331
—
—
—
—
—
13
45
233
2432
Removal of sutures
SPAT1153 [2001700254]
4.9e-02
8.4e-01
—
—
—
1.2e+00
9.1e-01
cases:5.90%
controls:5.63%
cases:2.95%
controls:1.30%
—
—
—
—
—
—
cases:3.77%
controls:1.15%
cases:9.35%
controls:4.00%
20
191
319
3199
10
44
329
3346
—
—
—
12
37
306
3185
23
99
223
2378
General anaesthesia
WX402 [2001310806]
1.0e+00
9.9e-01
—
—
—
1.3e+00
1.0e+00
cases:7.96%
controls:2.95%
cases:2.95%
controls:1.12%
—
—
—
—
—
—
cases:3.46%
controls:0.99%
cases:8.13%
controls:3.03%
27
100
312
3290
10
38
329
3352
—
—
—
11
32
307
3190
20
75
226
2402
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
—
2.0e+00
—
—
—
—
2.1e+00
—
—
cases:1.47%
controls:0.21%
—
—
—
—
—
—
—
—
cases:2.85%
controls:0.36%
—
5
7
334
3383
—
—
—
—
7
9
239
2468
hydrocortisone
C05AA01 [21601608]
2.9e-01
3.7e-01
—
—
—
1.3e+00
7.9e-01
cases:8.85%
controls:6.76%
cases:2.95%
controls:2.06%
—
—
—
—
—
—
cases:6.29%
controls:1.86%
cases:11.79%
controls:5.69%
30
229
309
3161
10
70
329
3320
—
—
—
20
60
298
3162
29
141
217
2336
hydrocortisone
A07EA02 [21600654]
2.9e-01
3.7e-01
—
—
—
1.3e+00
7.9e-01
cases:8.85%
controls:6.76%
cases:2.95%
controls:2.06%
—
—
—
—
—
—
cases:6.29%
controls:1.86%
cases:11.79%
controls:5.69%
30
229
309
3161
10
70
329
3320
—
—
—
20
60
298
3162
29
141
217
2336
Scheduled procedure
ZXD10 [2001311387]
8.5e-01
—
—
—
—
9.1e-01
1.2e+00
cases:10.32%
controls:4.69%
—
—
—
—
—
—
—
—
cases:2.20%
controls:0.90%
cases:8.54%
controls:2.75%
35
159
304
3231
—
—
—
—
7
29
311
3193
21
68
225
2409
Rhinopharyngoscopy
UDH02 [2001301680]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.44%
controls:0.32%
—
—
—
—
—
—
6
8
240
2469
Palpitations/awareness of heart
K04 [2002000547]
2.0e+00
—
—
—
—
—
—
cases:1.77%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
333
3382
—
—
—
—
—
—
Observation for suspected nervous system disorder
Z03.3 [45609903]
2.0e+00
—
—
—
—
—
—
cases:1.77%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
333
3382
—
—
—
—
—
—
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
313 [2001600274]
2.0e+00
—
—
—
—
—
—
cases:1.77%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
333
3382
—
—
—
—
—
—
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
2.0e+00
—
—
—
—
—
—
cases:3.24%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
—
—
11
15
328
3375
—
—
—
—
—
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
3.3e-01
6.6e-01
8.5e-01
—
1.3e+00
5.6e-01
5.0e-01
cases:15.93%
controls:12.04%
cases:10.91%
controls:5.93%
cases:2.65%
controls:1.15%
—
—
cases:3.25%
controls:0.89%
cases:10.06%
controls:6.02%
cases:20.33%
controls:13.36%
54
408
285
2982
37
201
302
3189
9
39
330
3351
—
11
30
327
3349
32
194
286
3028
50
331
196
2146
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
4.3e-01
9.3e-01
—
—
—
2.0e+00
1.2e+00
cases:2.95%
controls:1.95%
cases:1.77%
controls:0.71%
—
—
—
—
—
—
cases:3.46%
controls:0.50%
cases:4.88%
controls:1.49%
10
66
329
3324
6
24
333
3366
—
—
—
11
16
307
3206
12
37
234
2440
No procedures
SPAT1301 [2001700402]
4.5e-01
7.6e-01
1.4e+00
—
2.0e+00
3.4e-01
5.2e-01
cases:7.96%
controls:5.25%
cases:3.54%
controls:1.68%
cases:1.47%
controls:0.35%
—
—
cases:2.07%
controls:0.30%
cases:3.14%
controls:2.27%
cases:7.32%
controls:4.48%
27
178
312
3212
12
57
327
3333
5
12
334
3378
—
7
10
331
3369
10
73
308
3149
18
111
228
2366
Gout
M10 [45533711]
8.8e-01
—
—
—
—
—
1.9e+00
cases:1.47%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:0.48%
5
21
334
3369
—
—
—
—
—
8
12
238
2465
CBC panel - Blood by Automated count
58410-2 [40761511]
8.9e-02
5.1e-02
8.4e-01
—
1.1e+00
1.6e-01
3.1e-01
cases:39.82%
controls:37.70%
cases:24.19%
controls:23.27%
cases:8.85%
controls:4.01%
—
—
cases:10.95%
controls:4.02%
cases:24.84%
controls:21.91%
cases:44.31%
controls:36.74%
135
1278
204
2112
82
789
257
2601
30
136
309
3254
—
37
136
301
3243
79
706
239
2516
109
910
137
1567
Antithrombin actual/normal in Platelet poor plasma by Chromogenic method
27811-9 [3000515]
1.9e+00
—
—
—
—
—
—
cases:3.24%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
11
17
328
3373
—
—
—
—
—
—
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
9.4e-01
6.7e-01
—
—
—
8.4e-01
9.4e-01
cases:9.44%
controls:3.89%
cases:1.77%
controls:0.91%
—
—
—
—
—
—
cases:1.57%
controls:0.68%
cases:8.54%
controls:3.51%
32
132
307
3258
6
31
333
3359
—
—
—
5
22
313
3200
21
87
225
2390
Diarrhoea
D11 [2002000310]
6.4e-01
—
—
—
—
1.9e+00
9.4e-01
cases:1.77%
controls:0.94%
—
—
—
—
—
—
—
—
cases:2.20%
controls:0.34%
cases:2.44%
controls:0.97%
6
32
333
3358
—
—
—
—
7
11
311
3211
6
24
240
2453
Monitored bed care
WX892 [2001310850]
1.9e+00
-1.0e+50
—
—
—
-1.0e+50
—
cases:4.42%
controls:0.71%
cases:0.00%
controls:0.15%
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
15
24
324
3366
0
5
339
3385
—
—
—
0
5
318
3217
—
Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay
3255-7 [3016407]
1.9e+00
—
—
—
—
—
—
cases:2.95%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
10
16
329
3374
—
—
—
—
—
—
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
7.5e-01
6.6e-01
—
—
—
3.3e-01
1.1e+00
cases:8.85%
controls:4.37%
cases:2.65%
controls:1.39%
—
—
—
—
—
—
cases:1.89%
controls:1.37%
cases:7.72%
controls:2.70%
30
148
309
3242
9
47
330
3343
—
—
—
6
44
312
3178
19
67
227
2410
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
7.5e-01
6.6e-01
—
—
—
3.3e-01
1.1e+00
cases:8.85%
controls:4.37%
cases:2.65%
controls:1.39%
—
—
—
—
—
—
cases:1.89%
controls:1.37%
cases:7.72%
controls:2.70%
30
148
309
3242
9
47
330
3343
—
—
—
6
44
312
3178
19
67
227
2410
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
5.5e-01
8.8e-01
1.8e+00
—
1.3e+00
9.6e-01
6.6e-01
cases:8.26%
controls:4.93%
cases:6.19%
controls:2.65%
cases:1.77%
controls:0.29%
—
—
cases:1.48%
controls:0.41%
cases:6.92%
controls:2.76%
cases:10.98%
controls:5.97%
28
167
311
3223
21
90
318
3300
6
10
333
3380
—
5
14
333
3365
22
89
296
3133
27
148
219
2329
Myeloperoxidase IgG Ab [Units/volume] in Serum
48404-8 [3049804]
1.8e+00
—
—
—
—
—
—
cases:2.36%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
8
13
331
3377
—
—
—
—
—
—
Urgent procedure
ZXD05 [2001311386]
8.1e-01
—
—
—
—
6.7e-01
1.0e+00
cases:6.78%
controls:3.13%
—
—
—
—
—
—
—
—
cases:1.57%
controls:0.81%
cases:6.50%
controls:2.46%
23
106
316
3284
—
—
—
—
5
26
313
3196
16
61
230
2416
Ultrasound examination of lower leg veins
PH2AE [2001309451]
1.1e+00
—
—
—
—
-1.0e+50
1.8e+00
cases:2.36%
controls:0.77%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:6.10%
controls:1.05%
8
26
331
3364
—
—
—
—
0
11
318
3211
15
26
231
2451
antibiotics in combination with corticosteroids
D01AA20 [21601918]
9.3e-01
—
—
—
—
—
1.8e+00
cases:2.06%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
cases:4.88%
controls:0.85%
7
28
332
3362
—
—
—
—
—
12
21
234
2456
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
8.4e-01
8.9e-01
—
—
—
6.5e-01
9.5e-01
cases:7.08%
controls:3.19%
cases:3.24%
controls:1.36%
—
—
—
—
—
—
cases:2.52%
controls:1.33%
cases:7.72%
controls:3.15%
24
108
315
3282
11
46
328
3344
—
—
—
8
43
310
3179
19
78
227
2399
Rheumatoid/seropositive arthritis
L88 [2002000707]
1.6e+00
—
—
—
—
—
1.8e+00
cases:2.06%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:0.57%
7
14
332
3376
—
—
—
—
—
8
14
238
2463
Myoglobin [Mass/volume] in Serum or Plasma
2639-3 [3005895]
1.8e+00
—
—
—
—
—
-1.0e+50
cases:2.36%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
8
14
331
3376
—
—
—
—
—
0
16
246
2461
Knee X-ray examination without contrast
NG1AA [2001308049]
6.5e-01
1.5e+00
—
—
—
—
1.7e+00
cases:2.06%
controls:1.09%
cases:1.77%
controls:0.41%
—
—
—
—
—
—
—
—
cases:4.88%
controls:0.89%
7
37
332
3353
6
14
333
3376
—
—
—
—
12
22
234
2455
betamethasone
A07EA04 [21600656]
7.4e-01
9.9e-01
—
—
—
8.4e-01
5.0e-01
cases:12.98%
controls:6.64%
cases:6.78%
controls:2.63%
—
—
—
—
—
—
cases:5.03%
controls:2.23%
cases:10.98%
controls:6.94%
44
225
295
3165
23
89
316
3301
—
—
—
16
72
302
3150
27
172
219
2305
betamethasone
S02BA07 [21605169]
7.4e-01
9.9e-01
—
—
—
8.4e-01
5.0e-01
cases:12.98%
controls:6.64%
cases:6.78%
controls:2.63%
—
—
—
—
—
—
cases:5.03%
controls:2.23%
cases:10.98%
controls:6.94%
44
225
295
3165
23
89
316
3301
—
—
—
16
72
302
3150
27
172
219
2305
betamethasone
D07AC01 [21602120]
7.4e-01
9.9e-01
—
—
—
8.4e-01
5.0e-01
cases:12.98%
controls:6.64%
cases:6.78%
controls:2.63%
—
—
—
—
—
—
cases:5.03%
controls:2.23%
cases:10.98%
controls:6.94%
44
225
295
3165
23
89
316
3301
—
—
—
16
72
302
3150
27
172
219
2305
betamethasone
C05AA05 [21601610]
7.4e-01
9.9e-01
—
—
—
8.4e-01
5.0e-01
cases:12.98%
controls:6.64%
cases:6.78%
controls:2.63%
—
—
—
—
—
—
cases:5.03%
controls:2.23%
cases:10.98%
controls:6.94%
44
225
295
3165
23
89
316
3301
—
—
—
16
72
302
3150
27
172
219
2305
erdosteine; oral
R05CB15 [21603394]
7.4e-01
1.7e+00
—
—
—
9.8e-01
8.1e-01
cases:5.01%
controls:2.45%
cases:4.13%
controls:0.77%
—
—
—
—
—
—
cases:2.52%
controls:0.96%
cases:6.50%
controls:2.99%
17
83
322
3307
14
26
325
3364
—
—
—
8
31
310
3191
16
74
230
2403
Hyperlipidaemia, unspecified
E78.5 [45537986]
6.1e-01
—
—
1.0e+50
—
1.7e+00
5.0e-01
cases:2.36%
controls:1.30%
—
—
—
—
cases:2.06%
controls:0.00%
—
—
cases:2.52%
controls:0.47%
cases:2.44%
controls:1.49%
8
44
331
3346
—
—
7
0
332
3390
—
8
15
310
3207
6
37
240
2440
Other healthcare associate professional
Z3229 [2001311561]
1.4e+00
—
—
—
—
—
1.7e+00
cases:2.36%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:0.61%
8
21
331
3369
—
—
—
—
—
8
15
238
2462
Hyperplasia of prostate
N40 [45563015]
2.8e-01
1.1e-01
—
—
—
9.8e-01
7.3e-01
cases:8.26%
controls:6.34%
cases:3.24%
controls:2.92%
—
—
—
—
—
—
cases:7.23%
controls:2.86%
cases:12.20%
controls:6.30%
28
215
311
3175
11
99
328
3291
—
—
—
23
92
295
3130
30
156
216
2321
Acute tubulo-interstitial nephritis
N10 [45543856]
8.5e-02
—
—
—
—
1.7e+00
7.2e-01
cases:1.47%
controls:1.36%
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.59%
cases:3.25%
controls:1.61%
5
46
334
3344
—
—
—
—
10
19
308
3203
8
40
238
2437
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
4.6e-01
8.6e-01
1.3e+00
—
1.6e+00
8.4e-01
6.0e-01
cases:16.81%
controls:11.33%
cases:8.55%
controls:3.81%
cases:2.06%
controls:0.56%
—
—
cases:1.78%
controls:0.36%
cases:7.55%
controls:3.41%
cases:17.48%
controls:10.38%
57
384
282
3006
29
129
310
3261
7
19
332
3371
—
6
12
332
3367
24
110
294
3112
43
257
203
2220
Giving the first information
R2110 [2001310194]
1.7e+00
-1.0e+50
—
—
—
—
—
cases:2.36%
controls:0.44%
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
8
15
331
3375
0
6
339
3384
—
—
—
—
—
triamcinolone; nasal
R01AD11 [21605052]
1.7e+00
—
—
—
—
—
—
cases:2.65%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
9
17
330
3373
—
—
—
—
—
—
Thrombin time
3243-3 [3036489]
1.7e+00
—
—
—
—
—
—
cases:3.24%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
—
11
21
328
3369
—
—
—
—
—
—
Thorax X-ray examination
GD1AA [2001303617]
5.2e-01
5.4e-01
—
—
—
8.2e-01
8.3e-01
cases:13.86%
controls:8.70%
cases:5.60%
controls:3.33%
—
—
—
—
—
—
cases:7.55%
controls:3.48%
cases:18.70%
controls:9.12%
47
295
292
3095
19
113
320
3277
—
—
—
24
112
294
3110
46
226
200
2251
Primary arthrosis of other joints
M19.0 [45601353]
6.6e-01
—
—
—
—
—
1.6e+00
cases:1.47%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
cases:3.66%
controls:0.73%
5
26
334
3364
—
—
—
—
—
9
18
237
2459
Day surgery
ZXD20 [2001311388]
1.5e+00
-1.0e+50
—
—
—
-1.0e+50
1.6e+00
cases:2.36%
controls:0.56%
cases:0.00%
controls:0.21%
—
—
—
—
—
—
cases:0.00%
controls:0.28%
cases:3.25%
controls:0.65%
8
19
331
3371
0
7
339
3383
—
—
—
0
9
318
3213
8
16
238
2461
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
8.8e-01
7.3e-01
1.4e+00
—
—
7.3e-01
7.2e-01
cases:10.32%
controls:4.54%
cases:5.60%
controls:2.77%
cases:1.47%
controls:0.35%
—
—
—
—
cases:5.97%
controls:2.98%
cases:13.41%
controls:6.98%
35
154
304
3236
19
94
320
3296
5
12
334
3378
—
—
19
96
299
3126
33
173
213
2304
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
8.2e-01
1.0e+00
—
—
—
1.2e+00
1.6e+00
cases:5.31%
controls:2.42%
cases:2.06%
controls:0.77%
—
—
—
—
—
—
cases:2.52%
controls:0.81%
cases:6.91%
controls:1.49%
18
82
321
3308
7
26
332
3364
—
—
—
8
26
310
3196
17
37
229
2440
Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay
46082-4 [3046524]
1.6e+00
—
—
—
—
—
—
cases:2.95%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
—
10
21
329
3369
—
—
—
—
—
—
Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay
46083-2 [3043362]
1.6e+00
—
—
—
—
—
—
cases:2.95%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
—
10
21
329
3369
—
—
—
—
—
—
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
7.3e-01
8.5e-01
9.6e-01
—
9.4e-01
6.1e-01
5.2e-01
cases:22.42%
controls:12.18%
cases:15.04%
controls:7.05%
cases:3.54%
controls:1.39%
—
—
cases:3.85%
controls:1.54%
cases:11.64%
controls:6.70%
cases:20.73%
controls:13.40%
76
413
263
2977
51
239
288
3151
12
47
327
3343
—
13
52
325
3327
37
216
281
3006
51
332
195
2145
duloxetine; oral
N06AX21 [21604749]
1.0e+00
—
—
—
-1.0e+50
—
1.6e+00
cases:2.06%
controls:0.77%
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
cases:4.88%
controls:1.05%
7
26
332
3364
—
—
—
0
9
338
3370
—
12
26
234
2451
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
1.1e+00
—
—
—
—
—
1.6e+00
cases:1.47%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
cases:4.47%
controls:0.97%
5
17
334
3373
—
—
—
—
—
11
24
235
2453
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
6.9e-01
8.5e-01
1.0e+00
—
1.0e+00
6.2e-01
5.1e-01
cases:21.24%
controls:11.95%
cases:14.75%
controls:6.90%
cases:3.54%
controls:1.33%
—
—
cases:3.85%
controls:1.45%
cases:11.64%
controls:6.64%
cases:20.33%
controls:13.32%
72
405
267
2985
50
234
289
3156
12
45
327
3345
—
13
49
325
3330
37
214
281
3008
50
330
196
2147
Hip symptom/complaint
L13 [2002000637]
1.4e-01
1.5e+00
—
—
—
9.4e-01
—
cases:2.36%
controls:2.06%
cases:2.65%
controls:0.59%
—
—
—
—
—
—
cases:1.57%
controls:0.62%
—
—
8
70
331
3320
9
20
330
3370
—
—
—
5
20
313
3202
—
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
6.3e-01
6.3e-01
—
—
—
5.4e-01
8.9e-01
cases:19.47%
controls:11.39%
cases:5.60%
controls:3.07%
—
—
—
—
—
—
cases:5.97%
controls:3.57%
cases:21.95%
controls:10.34%
66
386
273
3004
19
104
320
3286
—
—
—
19
115
299
3107
54
256
192
2221
phenoxymethylpenicillin; oral
J01CE02 [21602842]
6.3e-01
6.3e-01
—
—
—
5.4e-01
8.9e-01
cases:19.47%
controls:11.39%
cases:5.60%
controls:3.07%
—
—
—
—
—
—
cases:5.97%
controls:3.57%
cases:21.95%
controls:10.34%
66
386
273
3004
19
104
320
3286
—
—
—
19
115
299
3107
54
256
192
2221
doxycycline; oral, parenteral
J01AA02 [21602800]
6.4e-01
5.3e-01
—
—
—
8.6e-01
5.6e-01
cases:23.89%
controls:14.22%
cases:5.60%
controls:3.36%
—
—
—
—
—
—
cases:7.23%
controls:3.20%
cases:20.33%
controls:12.76%
81
482
258
2908
19
114
320
3276
—
—
—
23
103
295
3119
50
316
196
2161
zopiclone; oral
N05CF01 [21604654]
6.9e-01
6.6e-01
5.7e-01
—
6.2e-01
7.3e-01
8.0e-01
cases:12.09%
controls:6.43%
cases:7.37%
controls:3.95%
cases:2.06%
controls:1.18%
—
—
cases:2.07%
controls:1.12%
cases:7.55%
controls:3.79%
cases:12.20%
controls:5.89%
41
218
298
3172
25
134
314
3256
7
40
332
3350
—
7
38
331
3341
24
122
294
3100
30
146
216
2331
Respiratory infection other
R83 [2002000951]
3.1e-01
1.5e+00
—
—
—
—
-2.5e-01
cases:5.31%
controls:3.95%
cases:3.54%
controls:0.83%
—
—
—
—
—
—
—
—
cases:2.85%
controls:3.63%
18
134
321
3256
12
28
327
3362
—
—
—
—
7
90
239
2387
Cough
R05 [2002000886]
4.8e-01
1.1e+00
—
—
—
1.5e+00
7.6e-01
cases:5.90%
controls:3.75%
cases:2.65%
controls:0.91%
—
—
—
—
—
—
cases:3.46%
controls:0.81%
cases:6.10%
controls:2.95%
20
127
319
3263
9
31
330
3359
—
—
—
11
26
307
3196
15
73
231
2404
Pain general/multiple sites
A01 [2002000142]
1.5e+00
—
—
—
—
—
—
cases:2.65%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
—
9
21
330
3369
—
—
—
—
—
—
tetracycline; oral, parenteral
J01AA07 [21602805]
1.5e+00
—
—
—
—
1.9e+00
9.4e-01
cases:3.24%
controls:0.77%
—
—
—
—
—
—
—
—
cases:1.57%
controls:0.25%
cases:2.03%
controls:0.81%
11
26
328
3364
—
—
—
—
5
8
313
3214
5
20
241
2457
ciclesonide; nasal
R01AD13 [43534836]
3.6e-01
1.1e+00
-1.0e+50
—
—
1.1e+00
1.5e+00
cases:2.36%
controls:1.65%
cases:2.65%
controls:0.88%
cases:0.00%
controls:0.24%
—
—
—
—
cases:2.20%
controls:0.74%
cases:4.07%
controls:0.97%
8
56
331
3334
9
30
330
3360
0
8
339
3382
—
—
7
24
311
3198
10
24
236
2453
Examination and observation for other specified reasons
Z04.8 [45552063]
3.5e-01
—
—
—
—
—
1.5e+00
cases:2.36%
controls:1.68%
—
—
—
—
—
—
—
—
—
—
cases:4.07%
controls:0.97%
8
57
331
3333
—
—
—
—
—
10
24
236
2453
ciclesonide; inhalant
R03BA08 [21603291]
3.6e-01
1.1e+00
-1.0e+50
—
—
1.1e+00
1.5e+00
cases:2.36%
controls:1.65%
cases:2.65%
controls:0.88%
cases:0.00%
controls:0.24%
—
—
—
—
cases:2.20%
controls:0.74%
cases:4.07%
controls:0.97%
8
56
331
3334
9
30
330
3360
0
8
339
3382
—
—
7
24
311
3198
10
24
236
2453
Exposure to unspecified factor
X59 [45756412]
5.6e-01
—
—
—
—
9.0e-01
1.5e+00
cases:2.65%
controls:1.53%
—
—
—
—
—
—
—
—
cases:1.89%
controls:0.78%
cases:6.91%
controls:1.70%
9
52
330
3338
—
—
—
—
6
25
312
3197
17
42
229
2435
Bacterial infection, unspecified
A49.9 [45590816]
6.8e-01
—
—
—
—
1.2e+00
1.5e+00
cases:2.65%
controls:1.36%
—
—
—
—
—
—
—
—
cases:1.57%
controls:0.50%
cases:6.10%
controls:1.49%
9
46
330
3344
—
—
—
—
5
16
313
3206
15
37
231
2440
Pain, unspecified
R52.9 [45544151]
1.4e+00
—
—
—
—
1.5e+00
—
cases:2.95%
controls:0.71%
—
—
—
—
—
—
—
—
cases:1.57%
controls:0.34%
—
—
10
24
329
3366
—
—
—
—
5
11
313
3211
—
Neurology
13 [38004458]
6.8e-01
5.0e-01
—
—
1.3e+00
4.7e-01
7.7e-01
cases:14.75%
controls:8.05%
cases:6.19%
controls:3.83%
—
—
—
—
cases:2.66%
controls:0.71%
cases:6.29%
controls:4.03%
cases:15.85%
controls:8.03%
50
273
289
3117
21
130
318
3260
—
—
9
24
329
3355
20
130
298
3092
39
199
207
2278
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
6.2e-01
1.7e+00
—
1.0e+50
—
1.2e+00
1.4e+00
cases:4.13%
controls:2.27%
cases:1.77%
controls:0.32%
—
—
cases:1.47%
controls:0.00%
—
—
cases:3.14%
controls:0.96%
cases:7.72%
controls:1.94%
14
77
325
3313
6
11
333
3379
—
5
0
334
3390
—
10
31
308
3191
19
48
227
2429
hydroxyzine; oral, parenteral
N05BB01 [21604590]
7.6e-01
1.4e+00
—
—
—
—
1.4e+00
cases:3.54%
controls:1.68%
cases:2.36%
controls:0.59%
—
—
—
—
—
—
—
—
cases:4.07%
controls:1.01%
12
57
327
3333
8
20
331
3370
—
—
—
—
10
25
236
2452
fluticasone; inhalant
R03BA05 [21603288]
7.3e-01
1.0e+00
—
—
—
1.4e+00
5.5e-01
cases:3.83%
controls:1.89%
cases:2.36%
controls:0.86%
—
—
—
—
—
—
cases:3.14%
controls:0.78%
cases:3.66%
controls:2.14%
13
64
326
3326
8
29
331
3361
—
—
—
10
25
308
3197
9
53
237
2424
prednisone; oral
H02AB07 [21602735]
1.4e+00
—
—
—
—
1.5e+00
8.9e-01
cases:4.13%
controls:1.03%
—
—
—
—
—
—
—
—
cases:1.57%
controls:0.34%
cases:2.03%
controls:0.85%
14
35
325
3355
—
—
—
—
5
11
313
3211
5
21
241
2456
prednisone
A07EA03 [21600655]
1.4e+00
—
—
—
—
1.5e+00
8.9e-01
cases:4.13%
controls:1.03%
—
—
—
—
—
—
—
—
cases:1.57%
controls:0.34%
cases:2.03%
controls:0.85%
14
35
325
3355
—
—
—
—
5
11
313
3211
5
21
241
2456
Celiac disease serology panel - Serum
94494-2 [36660697]
1.4e+00
—
—
—
—
—
8.1e-01
cases:4.72%
controls:1.24%
—
—
—
—
—
—
—
—
—
—
cases:2.85%
controls:1.29%
16
42
323
3348
—
—
—
—
—
7
32
239
2445
pH of Urine
2756-5 [3015736]
5.9e-01
6.8e-01
1.3e+00
—
8.9e-01
7.8e-01
5.7e-01
cases:14.45%
controls:8.55%
cases:8.85%
controls:4.69%
cases:2.06%
controls:0.56%
—
—
cases:1.78%
controls:0.74%
cases:9.75%
controls:4.72%
cases:17.48%
controls:10.70%
49
290
290
3100
30
159
309
3231
7
19
332
3371
—
6
25
332
3354
31
152
287
3070
43
265
203
2212
Fever
A03 [2002000144]
8.8e-01
—
—
—
—
—
1.4e+00
cases:3.54%
controls:1.50%
—
—
—
—
—
—
—
—
—
—
cases:6.10%
controls:1.66%
12
51
327
3339
—
—
—
—
—
15
41
231
2436
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
1.2e+00
1.6e+00
—
—
—
—
1.3e+00
cases:3.54%
controls:1.09%
cases:2.06%
controls:0.44%
—
—
—
—
—
—
—
—
cases:6.10%
controls:1.70%
12
37
327
3353
7
15
332
3375
—
—
—
—
15
42
231
2435
tizanidine; oral
M03BX02 [21604116]
6.5e-01
4.9e-01
—
—
—
7.2e-01
6.6e-01
cases:16.81%
controls:9.56%
cases:5.01%
controls:3.13%
—
—
—
—
—
—
cases:5.66%
controls:2.82%
cases:14.63%
controls:8.16%
57
324
282
3066
17
106
322
3284
—
—
—
18
91
300
3131
36
202
210
2275
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1.2e+00
—
—
—
—
1.4e+00
1.3e+00
cases:3.24%
controls:0.97%
—
—
—
—
—
—
—
—
cases:2.20%
controls:0.56%
cases:5.28%
controls:1.49%
11
33
328
3357
—
—
—
—
7
18
311
3204
13
37
233
2440
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
1.3e+00
1.5e+00
—
—
—
—
9.4e-01
cases:7.96%
controls:2.39%
cases:2.36%
controls:0.53%
—
—
—
—
—
—
—
—
cases:3.25%
controls:1.29%
27
81
312
3309
8
18
331
3372
—
—
—
—
8
32
238
2445
Treatment plan or consultation
WZC00 [2001310885]
4.0e-01
1.3e+00
—
—
—
3.6e-01
1.4e-01
cases:7.67%
controls:5.25%
cases:4.42%
controls:1.30%
—
—
—
—
—
—
cases:2.52%
controls:1.77%
cases:5.69%
controls:5.01%
26
178
313
3212
15
44
324
3346
—
—
—
8
57
310
3165
14
124
232
2353
Extended examination of mouth
SAA03 [2001310276]
5.2e-01
1.3e+00
—
—
—
7.4e-01
3.6e-01
cases:7.96%
controls:4.90%
cases:3.83%
controls:1.12%
—
—
—
—
—
—
cases:2.52%
controls:1.21%
cases:6.91%
controls:4.93%
27
166
312
3224
13
38
326
3352
—
—
—
8
39
310
3183
17
122
229
2355
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
6.8e-01
—
—
—
—
—
1.2e+00
cases:3.83%
controls:1.98%
—
—
—
—
—
—
—
—
—
—
cases:5.28%
controls:1.57%
13
67
326
3323
—
—
—
—
—
13
39
233
2438
Abdominal CT examination
JN3AD [2001305554]
2.3e-01
—
—
—
-1.0e+50
4.7e-01
1.2e+00
cases:1.47%
controls:1.18%
—
—
—
—
—
—
cases:0.00%
controls:0.15%
cases:1.57%
controls:0.99%
cases:5.69%
controls:1.74%
5
40
334
3350
—
—
—
0
5
338
3374
5
32
313
3190
14
43
232
2434
hydrocortisone aceponate
D07AC16 [21602135]
3.1e-01
4.0e-01
—
—
—
1.2e+00
7.2e-01
cases:8.85%
controls:6.64%
cases:2.95%
controls:2.01%
—
—
—
—
—
—
cases:5.97%
controls:1.86%
cases:10.98%
controls:5.65%
30
225
309
3165
10
68
329
3322
—
—
—
19
60
299
3162
27
140
219
2337
hydrocortisone buteprate
D07AB11 [21602115]
3.1e-01
4.0e-01
—
—
—
1.2e+00
7.2e-01
cases:8.85%
controls:6.64%
cases:2.95%
controls:2.01%
—
—
—
—
—
—
cases:5.97%
controls:1.86%
cases:10.98%
controls:5.65%
30
225
309
3165
10
68
329
3322
—
—
—
19
60
299
3162
27
140
219
2337
hydrocortisone butyrate
D07AB02 [21602106]
3.1e-01
4.0e-01
—
—
—
1.2e+00
7.2e-01
cases:8.85%
controls:6.64%
cases:2.95%
controls:2.01%
—
—
—
—
—
—
cases:5.97%
controls:1.86%
cases:10.98%
controls:5.65%
30
225
309
3165
10
68
329
3322
—
—
—
19
60
299
3162
27
140
219
2337
hydrocortisone
D07AA02 [21602102]
3.1e-01
4.0e-01
—
—
—
1.2e+00
7.2e-01
cases:8.85%
controls:6.64%
cases:2.95%
controls:2.01%
—
—
—
—
—
—
cases:5.97%
controls:1.86%
cases:10.98%
controls:5.65%
30
225
309
3165
10
68
329
3322
—
—
—
19
60
299
3162
27
140
219
2337
Plastic And Reconstructive Surgery
24 [38004467]
6.5e-01
1.0e+00
—
1.0e+50
2.1e+00
1.3e+00
1.2e+00
cases:3.54%
controls:1.89%
cases:1.77%
controls:0.65%
—
—
cases:2.95%
controls:0.00%
cases:1.48%
controls:0.18%
cases:3.14%
controls:0.84%
cases:6.10%
controls:1.94%
12
64
327
3326
6
22
333
3368
—
10
0
329
3390
5
6
333
3373
10
27
308
3195
15
48
231
2429
escitalopram; oral
N06AB10 [21604718]
3.3e-01
5.0e-01
—
—
—
1.2e+00
8.6e-01
cases:3.54%
controls:2.57%
cases:2.65%
controls:1.62%
—
—
—
—
—
—
cases:4.40%
controls:1.43%
cases:6.50%
controls:2.87%
12
87
327
3303
9
55
330
3335
—
—
—
14
46
304
3176
16
71
230
2406
nepafenac
S01BC10 [21603648]
1.1e+00
—
—
—
—
—
—
cases:4.13%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
—
—
14
46
325
3344
—
—
—
—
—
—
More than one and less than three hours
ZXE10 [2001311401]
4.4e-01
—
—
—
—
8.1e-01
1.1e+00
cases:7.37%
controls:4.90%
—
—
—
—
—
—
—
—
cases:2.20%
controls:0.99%
cases:7.72%
controls:2.70%
25
166
314
3224
—
—
—
—
7
32
311
3190
19
67
227
2410
Sedation and analgesia
WX002 [2001310758]
1.1e+00
—
—
—
—
—
8.5e-01
cases:7.37%
controls:2.65%
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:1.41%
25
90
314
3300
—
—
—
—
—
8
35
238
2442
glucosamine; oral
M01AX05 [21604002]
1.3e-01
8.9e-01
—
—
—
1.3e+00
1.1e+00
cases:2.95%
controls:2.60%
cases:1.77%
controls:0.74%
—
—
—
—
—
—
cases:2.52%
controls:0.71%
cases:6.91%
controls:2.50%
10
88
329
3302
6
25
333
3365
—
—
—
8
23
310
3199
17
62
229
2415
bisoprolol; oral
C07AB07 [21601689]
4.1e-01
4.8e-01
5.5e-01
—
2.1e-01
5.8e-01
4.0e-01
cases:23.30%
controls:16.84%
cases:22.71%
controls:15.43%
cases:8.55%
controls:5.13%
—
—
cases:5.92%
controls:4.85%
cases:25.16%
controls:15.83%
cases:26.02%
controls:19.06%
79
571
260
2819
77
523
262
2867
29
174
310
3216
—
20
164
318
3215
80
510
238
2712
64
472
182
2005
beclometasone; inhalant
R03BA01 [21603284]
1.1e+00
1.3e+00
—
—
—
6.0e-01
4.9e-01
cases:4.42%
controls:1.59%
cases:2.95%
controls:0.80%
—
—
—
—
—
—
cases:1.57%
controls:0.87%
cases:2.03%
controls:1.25%
15
54
324
3336
10
27
329
3363
—
—
—
5
28
313
3194
5
31
241
2446
FEV1 percent change
69983-5 [42868472]
1.1e+00
9.3e-01
—
—
—
1.2e+00
1.2e+00
cases:5.60%
controls:2.04%
cases:2.06%
controls:0.83%
—
—
—
—
—
—
cases:1.57%
controls:0.50%
cases:3.66%
controls:1.09%
19
69
320
3321
7
28
332
3362
—
—
—
5
16
313
3206
9
27
237
2450
FVC percent change Respiratory system
69982-7 [42868471]
1.1e+00
9.3e-01
—
—
—
1.2e+00
1.2e+00
cases:5.60%
controls:2.04%
cases:2.06%
controls:0.83%
—
—
—
—
—
—
cases:1.57%
controls:0.50%
cases:3.66%
controls:1.09%
19
69
320
3321
7
28
332
3362
—
—
—
5
16
313
3206
9
27
237
2450
FEV1/FVC --post bronchodilation
69970-2 [42868459]
1.1e+00
9.3e-01
—
—
—
1.2e+00
1.2e+00
cases:5.60%
controls:2.04%
cases:2.06%
controls:0.83%
—
—
—
—
—
—
cases:1.57%
controls:0.50%
cases:3.66%
controls:1.09%
19
69
320
3321
7
28
332
3362
—
—
—
5
16
313
3206
9
27
237
2450
FEV1 --post bronchodilation
20155-8 [3023550]
1.1e+00
9.3e-01
—
—
—
1.2e+00
1.2e+00
cases:5.60%
controls:2.04%
cases:2.06%
controls:0.83%
—
—
—
—
—
—
cases:1.57%
controls:0.50%
cases:3.66%
controls:1.09%
19
69
320
3321
7
28
332
3362
—
—
—
5
16
313
3206
9
27
237
2450
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
1.1e+00
9.3e-01
—
—
—
1.2e+00
1.2e+00
cases:5.60%
controls:2.04%
cases:2.06%
controls:0.83%
—
—
—
—
—
—
cases:1.57%
controls:0.50%
cases:3.66%
controls:1.09%
19
69
320
3321
7
28
332
3362
—
—
—
5
16
313
3206
9
27
237
2450
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
1.0e+00
9.3e-01
—
—
—
—
1.6e-01
cases:4.13%
controls:1.50%
cases:1.77%
controls:0.71%
—
—
—
—
—
—
—
—
cases:2.03%
controls:1.74%
14
51
325
3339
6
24
333
3366
—
—
—
—
5
43
241
2434
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
5.0e-01
3.4e-01
—
—
—
3.7e-01
1.0e+00
cases:10.03%
controls:6.34%
cases:2.95%
controls:2.12%
—
—
—
—
—
—
cases:3.77%
controls:2.64%
cases:16.67%
controls:6.66%
34
215
305
3175
10
72
329
3318
—
—
—
12
85
306
3137
41
165
205
2312
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
7.3e-01
9.3e-01
—
—
—
1.0e+00
4.0e-01
cases:6.49%
controls:3.24%
cases:4.72%
controls:1.92%
—
—
—
—
—
—
cases:5.03%
controls:1.86%
cases:6.10%
controls:4.16%
22
110
317
3280
16
65
323
3325
—
—
—
16
60
302
3162
15
103
231
2374
Issue of repeat prescription
Z76.0 [45542456]
7.6e-01
6.4e-01
—
—
—
1.0e+00
3.6e-01
cases:5.31%
controls:2.57%
cases:2.65%
controls:1.42%
—
—
—
—
—
—
cases:5.03%
controls:1.86%
cases:6.91%
controls:4.93%
18
87
321
3303
9
48
330
3342
—
—
—
16
60
302
3162
17
122
229
2355
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
7.3e-01
8.8e-01
—
—
—
1.0e+00
2.8e-01
cases:7.08%
controls:3.54%
cases:4.72%
controls:2.01%
—
—
—
—
—
—
cases:5.35%
controls:1.99%
cases:5.69%
controls:4.36%
24
120
315
3270
16
68
323
3322
—
—
—
17
64
301
3158
14
108
232
2369
12 lead EKG panel
34534-8 [3044889]
4.6e-01
-3.2e-03
1.2e+00
—
7.0e-01
5.2e-01
5.5e-01
cases:30.38%
controls:21.53%
cases:10.32%
controls:10.35%
cases:2.36%
controls:0.74%
—
—
cases:2.37%
controls:1.18%
cases:15.41%
controls:9.78%
cases:33.33%
controls:22.37%
103
730
236
2660
35
351
304
3039
8
25
331
3365
—
8
40
330
3339
49
315
269
2907
82
554
164
1923
tiotropium bromide; inhalant
R03BB04 [21603296]
1.0e+00
6.5e-01
9.2e-01
—
1.2e+00
8.0e-01
8.5e-01
cases:5.01%
controls:1.89%
cases:2.95%
controls:1.56%
cases:1.47%
controls:0.59%
—
—
cases:1.48%
controls:0.44%
cases:3.46%
controls:1.58%
cases:5.69%
controls:2.50%
17
64
322
3326
10
53
329
3337
5
20
334
3370
—
5
15
333
3364
11
51
307
3171
14
62
232
2415
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
6.7e-01
9.0e-01
—
—
2.3e+00
9.7e-01
1.0e+00
cases:3.24%
controls:1.68%
cases:2.36%
controls:0.97%
—
—
—
—
cases:1.48%
controls:0.15%
cases:2.83%
controls:1.09%
cases:6.50%
controls:2.50%
11
57
328
3333
8
33
331
3357
—
—
5
5
333
3374
9
35
309
3187
16
62
230
2415
ECG with 12 standard connections
XF400 [2001303368]
9.8e-01
—
—
—
—
—
1.5e+00
cases:5.90%
controls:2.30%
—
—
—
—
—
—
—
—
—
—
cases:2.85%
controls:0.65%
20
78
319
3312
—
—
—
—
—
7
16
239
2461
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
9.7e-01
9.6e-01
—
—
—
4.5e-01
7.4e-01
cases:8.85%
controls:3.54%
cases:3.54%
controls:1.39%
—
—
—
—
—
—
cases:1.89%
controls:1.21%
cases:7.72%
controls:3.84%
30
120
309
3270
12
47
327
3343
—
—
—
6
39
312
3183
19
95
227
2382
Pneumonia, unspecified
J18.9 [45601123]
9.7e-01
—
—
—
—
3.3e-01
4.9e-01
cases:7.08%
controls:2.80%
—
—
—
—
—
—
—
—
cases:1.89%
controls:1.37%
cases:7.72%
controls:4.88%
24
95
315
3295
—
—
—
—
6
44
312
3178
19
121
227
2356
Specific gravity of Urine by Refractometry
5810-7 [3019150]
-2.8e-01
2.4e-01
—
—
—
9.7e-01
6.0e-01
cases:3.54%
controls:4.63%
cases:3.54%
controls:2.80%
—
—
—
—
—
—
cases:5.97%
controls:2.36%
cases:10.57%
controls:6.10%
12
157
327
3233
12
95
327
3295
—
—
—
19
76
299
3146
26
151
220
2326
Supine thorax X-ray examination
GD1QA [2001303648]
3.5e-01
8.3e-01
-1.0e+50
—
—
5.0e-01
9.4e-01
cases:2.36%
controls:1.68%
cases:1.47%
controls:0.65%
cases:0.00%
controls:0.15%
—
—
—
—
cases:1.89%
controls:1.15%
cases:7.32%
controls:2.99%
8
57
331
3333
5
22
334
3368
0
5
339
3385
—
—
6
37
312
3185
18
74
228
2403
Spirometry study
18759-1 [3000492]
9.3e-01
—
—
—
—
-1.0e+50
8.4e-01
cases:5.01%
controls:2.04%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
cases:4.47%
controls:1.98%
17
69
322
3321
—
—
—
—
0
15
318
3207
11
49
235
2428
Low back symptom/complaint
L03 [2002000628]
9.3e-01
3.2e-01
—
—
—
1.1e+00
6.9e-01
cases:7.96%
controls:3.30%
cases:2.06%
controls:1.50%
—
—
—
—
—
—
cases:3.46%
controls:1.18%
cases:7.72%
controls:4.04%
27
112
312
3278
7
51
332
3339
—
—
—
11
38
307
3184
19
100
227
2377
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
4.2e-01
6.0e-01
7.0e-01
—
1.1e+00
4.5e-01
9.2e-01
cases:15.34%
controls:10.68%
cases:9.14%
controls:5.25%
cases:1.77%
controls:0.88%
—
—
cases:2.37%
controls:0.77%
cases:8.18%
controls:5.37%
cases:21.95%
controls:10.05%
52
362
287
3028
31
178
308
3212
6
30
333
3360
—
8
26
330
3353
26
173
292
3049
54
249
192
2228
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
9.1e-01
8.3e-01
—
—
—
8.0e-01
9.7e-01
cases:5.60%
controls:2.33%
cases:2.06%
controls:0.91%
—
—
—
—
—
—
cases:1.57%
controls:0.71%
cases:3.66%
controls:1.41%
19
79
320
3311
7
31
332
3359
—
—
—
5
23
313
3199
9
35
237
2442
FEV1/FVC
19926-5 [3011505]
9.1e-01
8.3e-01
—
—
—
8.0e-01
9.7e-01
cases:5.60%
controls:2.33%
cases:2.06%
controls:0.91%
—
—
—
—
—
—
cases:1.57%
controls:0.71%
cases:3.66%
controls:1.41%
19
79
320
3311
7
31
332
3359
—
—
—
5
23
313
3199
9
35
237
2442
Malaise and fatigue
R53 [45553741]
9.1e-01
8.3e-01
—
—
—
9.0e-01
6.0e-01
cases:5.60%
controls:2.33%
cases:2.65%
controls:1.18%
—
—
—
—
—
—
cases:3.14%
controls:1.30%
cases:6.91%
controls:3.92%
19
79
320
3311
9
40
330
3350
—
—
—
10
42
308
3180
17
97
229
2380
FEV1
20150-9 [3024653]
9.1e-01
8.3e-01
—
—
—
8.0e-01
9.7e-01
cases:5.60%
controls:2.33%
cases:2.06%
controls:0.91%
—
—
—
—
—
—
cases:1.57%
controls:0.71%
cases:3.66%
controls:1.41%
19
79
320
3311
7
31
332
3359
—
—
—
5
23
313
3199
9
35
237
2442
omeprazole; oral, parenteral
A02BC01 [21600096]
4.8e-01
5.7e-01
1.8e+00
—
1.1e+00
6.9e-01
9.1e-01
cases:6.19%
controls:3.92%
cases:3.24%
controls:1.86%
cases:1.47%
controls:0.24%
—
—
cases:1.48%
controls:0.47%
cases:3.77%
controls:1.92%
cases:7.72%
controls:3.27%
21
133
318
3257
11
63
328
3327
5
8
334
3382
—
5
16
333
3363
12
62
306
3160
19
81
227
2396
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
5.3e-01
8.5e-01
1.0e+00
1.0e+50
1.0e+00
6.1e-01
9.0e-01
cases:10.03%
controls:6.17%
cases:5.01%
controls:2.21%
cases:1.47%
controls:0.53%
cases:1.47%
controls:0.00%
cases:1.48%
controls:0.53%
cases:4.72%
controls:2.61%
cases:13.82%
controls:6.14%
34
209
305
3181
17
75
322
3315
5
18
334
3372
5
0
334
3390
5
18
333
3361
15
84
303
3138
34
152
212
2325
esomeprazole; oral, parenteral
A02BC05 [21600100]
3.4e-01
2.6e-01
—
—
—
8.7e-01
3.7e-01
cases:9.44%
controls:6.90%
cases:3.83%
controls:2.98%
—
—
—
—
—
—
cases:6.60%
controls:2.89%
cases:9.35%
controls:6.62%
32
234
307
3156
13
101
326
3289
—
—
—
21
93
297
3129
23
164
223
2313
Gastroenterology
10 [38004455]
3.7e-01
8.4e-01
—
—
—
1.9e-01
8.6e-01
cases:7.37%
controls:5.22%
cases:4.72%
controls:2.09%
—
—
—
—
—
—
cases:2.83%
controls:2.36%
cases:9.76%
controls:4.36%
25
177
314
3213
16
71
323
3319
—
—
—
9
76
309
3146
24
108
222
2369
Other and unspecified abdominal pain
R10.4 [45568113]
8.6e-01
4.6e-01
—
—
-1.0e+50
1.2e-01
6.9e-01
cases:8.55%
controls:3.81%
cases:1.77%
controls:1.12%
—
—
—
—
cases:0.00%
controls:0.24%
cases:1.57%
controls:1.40%
cases:7.32%
controls:3.79%
29
129
310
3261
6
38
333
3352
—
—
0
8
338
3371
5
45
313
3177
18
94
228
2383
candesartan; oral
C09CA06 [21601829]
8.5e-01
6.4e-01
7.3e-01
—
5.2e-01
4.3e-01
5.2e-01
cases:11.21%
controls:5.13%
cases:8.55%
controls:4.72%
cases:2.65%
controls:1.30%
—
—
cases:2.07%
controls:1.24%
cases:7.23%
controls:4.84%
cases:10.57%
controls:6.54%
38
174
301
3216
29
160
310
3230
9
44
330
3346
—
7
42
331
3337
23
156
295
3066
26
162
220
2315
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
8.4e-01
3.0e-01
—
—
—
4.5e-01
-4.7e-02
cases:9.14%
controls:4.16%
cases:5.90%
controls:4.42%
—
—
—
—
—
—
cases:6.92%
controls:4.53%
cases:11.38%
controls:11.87%
31
141
308
3249
20
150
319
3240
—
—
—
22
146
296
3076
28
294
218
2183
calcium (different salts in combination); oral
A12AA20 [21600872]
5.4e-01
6.1e-01
3.6e-01
—
2.3e-01
6.1e-01
8.4e-01
cases:11.21%
controls:6.87%
cases:9.14%
controls:5.16%
cases:2.65%
controls:1.86%
—
—
cases:2.07%
controls:1.66%
cases:9.75%
controls:5.52%
cases:16.67%
controls:7.95%
38
233
301
3157
31
175
308
3215
9
63
330
3327
—
7
56
331
3323
31
178
287
3044
41
197
205
2280
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
8.4e-01
5.9e-01
—
—
—
9.4e-01
8.4e-01
cases:7.37%
controls:3.33%
cases:2.06%
controls:1.15%
—
—
—
—
—
—
cases:1.89%
controls:0.74%
cases:6.50%
controls:2.91%
25
113
314
3277
7
39
332
3351
—
—
—
6
24
312
3198
16
72
230
2405
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
8.3e-01
8.7e-01
—
—
—
7.2e-01
6.9e-01
cases:7.67%
controls:3.48%
cases:3.24%
controls:1.39%
—
—
—
—
—
—
cases:2.20%
controls:1.09%
cases:4.88%
controls:2.50%
26
118
313
3272
11
47
328
3343
—
—
—
7
35
311
3187
12
62
234
2415
Knee symptom/complaint
L15 [2002000639]
8.2e-01
9.3e-01
—
—
—
7.8e-01
8.6e-01
cases:6.49%
controls:2.98%
cases:2.36%
controls:0.94%
—
—
—
—
—
—
cases:2.20%
controls:1.02%
cases:6.50%
controls:2.87%
22
101
317
3289
8
32
331
3358
—
—
—
7
33
311
3189
16
71
230
2406

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
150
443
5.27
49.39
2.6
2.1
—
—
—
0
0
50
66
8.71
36.68
1.4
1.5
23904.47
10083.96
e6/l
0.95
30
49
40
55
8.11
28.18
1.6
1.3
—
—
—
0
0
173
910
2.83
19.79
7.0
4.6
—
—
—
0
0
143
755
2.54
15.28
3.7
3.2
357.35
371.08
umol/l
0.83
126
657
223
1453
2.55
14.98
8.8
7.5
1.20
1.20
mmol/l
0.05
204
1259
82
336
2.90
14.39
2.4
1.6
—
—
—
0
0
221
1466
2.45
13.78
10.4
6.4
0.61
0.62
e9/l
0.25
191
1262
238
1635
2.52
13.69
14.2
10.8
4.31
4.24
e9/l
0.17
207
1439
85
364
2.78
13.68
1.4
1.2
2.45
17.14
u/ml
2.32
23
138
220
1467
2.42
13.39
10.5
6.4
0.04
0.04
e9/l
0.30
188
1261
221
1486
2.39
13.06
10.5
6.4
1.65
1.85
e9/l
2.71
194
1310
151
872
2.32
12.66
5.4
4.5
7.40
7.40
ph
0.38
109
637
222
1508
2.36
12.63
11.1
6.7
0.17
0.19
e9/l
1.28
194
1322
113
587
2.39
11.98
6.1
3.9
260.58
516.68
ng/l
0.48
102
503
132
735
2.30
11.91
2.5
2.2
2.53
3.01
mg/l
1.02
122
634
104
523
2.42
11.84
4.4
2.8
0.59
1.00
e6/l
1.47
50
287
285
2199
2.83
11.80
11.7
8.9
85.44
81.60
u/l
0.47
278
2104
204
1363
2.24
11.71
10.8
6.4
2.73
2.86
%
0.33
197
1283
99
491
2.43
11.59
4.4
2.9
0.83
1.20
e6/l
0.42
45
257
203
1361
2.22
11.45
10.7
6.4
60.38
58.13
%
2.21
198
1308
203
1362
2.22
11.42
11.0
6.5
0.63
0.66
%
0.35
196
1277
204
1372
2.22
11.40
11.0
6.5
8.76
9.20
%
1.43
196
1290
198
1317
2.21
11.36
3.6
2.7
—
—
estimate
—
0
0
69
290
2.73
11.36
11.3
8.1
—
—
—
0
0
198
1319
2.20
11.29
9.0
6.7
1.20
1.20
mmol/l
0.24
192
1231
255
1886
2.41
11.23
6.2
4.1
—
1.91
—
0
5
86
411
2.46
10.85
1.4
1.2
27.87
36.17
iu/ml
0.32
26
131
76
343
2.57
10.82
2.8
2.8
12.50
9.97
umol/l
0.20
70
313
205
1400
2.17
10.78
10.8
6.5
24.42
26.48
%
2.18
200
1334
58
229
2.85
10.72
4.0
3.7
192.07
216.05
ng/l
0.24
53
206
71
318
2.56
10.23
4.9
3.6
1.24
1.76
mmol/l
0.52
65
262
72
326
2.53
10.14
4.8
3.6
7.37
7.38
ph
0.24
31
187
210
1472
2.12
10.01
23.4
14.9
1.32
1.28
inr
0.42
165
1223
189
1293
2.04
9.40
15.5
11.8
0.00
0.00
e9/l
0.49
147
1066
188
1286
2.03
9.32
2.6
2.1
94.18
92.82
pmol/l
0.16
107
705
107
595
2.16
9.30
3.0
1.6
1.32
1.44
mg/l
0.26
91
463
155
991
2.04
9.27
5.2
3.3
40.11
136.63
e6/l
0.79
120
767
167
1101
2.02
9.13
6.6
3.8
37.95
133.40
e6/l
0.87
121
795
214
1550
2.03
8.85
9.2
7.7
14.42
12.70
umol/l
0.37
207
1491
50
202
2.73
8.79
9.8
9.3
16.02
16.16
%
0.11
45
193
136
849
2.00
8.53
5.6
3.2
0.42
0.53
e6/l
0.20
99
632
68
325
2.37
8.42
5.1
3.6
5.89
5.76
kpa
0.54
68
315
110
640
2.06
8.36
4.7
3.6
—
0.38
—
0
8
69
336
2.32
8.18
1.5
1.3
305.88
430.29
titre
0.74
17
70
136
861
1.97
8.10
8.7
6.7
—
—
—
0
0
98
557
2.07
7.87
1.3
1.2
1.48
1.57
u/ml
0.05
18
157
59
276
2.38
7.63
2.8
2.1
33.31
35.23
u/l
0.17
49
230
168
1164
1.88
7.45
2.8
2.3
79.97
75.34
nmol/l
1.20
158
1048
186
1333
1.87
7.40
6.8
5.3
34.90
35.36
g/l
0.52
181
1264
175
1234
1.86
7.29
4.1
2.9
146.60
163.89
ug/l
0.46
170
1138
139
912
1.89
7.26
2.6
2.5
57.65
69.56
u/l
0.72
131
866
120
751
1.92
7.24
4.5
3.0
—
—
—
0
0
76
406
2.12
7.12
8.7
7.1
7.43
7.42
ph
0.49
32
238
75
409
2.07
6.63
8.7
7.0
1.66
0.89
mmol/l
0.60
62
333
110
686
1.89
6.61
3.7
2.7
3.62
4.12
e6/l
0.29
101
627
196
1472
1.78
6.29
5.4
3.5
0.00
0.01
estimate
0.50
32
277
74
409
2.03
6.28
8.9
7.1
5.12
5.11
kpa
0.02
69
393
74
409
2.03
6.28
8.9
7.1
11.64
12.08
kpa
0.34
69
394
40
171
2.52
6.26
1.3
1.2
—
—
—
0
0
95
574
1.91
6.24
4.0
3.0
537.67
572.98
mosm/kgh2o
1.07
85
504
55
272
2.22
6.22
4.5
3.1
5.02
4.52
kpa
0.48
55
261
239
1911
1.84
6.14
3.8
3.4
55.17
54.21
u/l
0.06
223
1801
314
2771
2.74
6.12
31.8
16.5
29.95
27.19
mg/l
0.76
287
2289
194
1461
1.76
6.08
5.3
3.5
0.00
0.01
estimate
0.50
33
299
28
102
2.90
5.95
2.6
5.9
1.25
1.33
mmol/l
0.26
21
89
69
381
2.02
5.85
1.7
1.4
—
—
—
0
0
252
2062
1.86
5.84
5.2
4.3
—
12627.25
—
0
8
15
27
5.76
5.75
2.3
1.6
9.60
9.61
%
0.00
15
27
43
198
2.34
5.73
3.6
2.9
128.77
133.07
g/l
0.57
43
193
278
2355
1.99
5.70
40.2
20.0
14.10
13.68
%
4.66
278
2323
190
1448
1.71
5.49
5.3
3.5
0.00
0.00
estimate
-0.00
33
298
160
1169
1.70
5.37
4.5
3.2
6.19
6.14
ph
0.19
82
680
137
960
1.72
5.36
3.4
2.4
—
—
—
0
0
86
526
1.85
5.36
1.6
1.5
2.50
2.74
g/l
0.66
52
342
34
147
2.46
5.20
3.0
2.0
1.40
1.52
g/l
0.30
27
133
125
862
1.71
5.14
1.9
1.7
19.21
19.71
nmol/l
0.14
114
719
16
45
3.68
5.11
2.1
2.0
0.72
0.94
g/l
0.26
11
37
65
372
1.92
4.94
1.4
1.3
—
—
—
0
0
38
181
2.24
4.69
3.9
2.8
0.60
0.64
%
0.32
38
181
10
14
7.32
4.68
1.2
1.4
—
—
—
0
0
21
75
2.92
4.64
5.0
2.9
1.33
3.05
index
0.84
12
44
38
184
2.20
4.51
3.9
2.8
1.18
1.13
%
0.14
38
184
130
942
1.62
4.26
4.7
3.5
1683.66
1541.86
ng/l
0.15
120
822
40
203
2.10
4.23
2.1
2.7
—
—
—
0
0
53
299
1.92
4.19
1.8
2.4
75.35
158.17
ug/g
2.32
43
244
141
1053
1.58
4.01
2.5
2.2
—
—
—
0
0
19
70
2.82
3.99
1.0
1.1
—
—
—
0
0
51
289
1.90
3.97
2.1
3.2
76.93
67.33
e9/l
0.99
36
218
92
621
1.66
3.95
4.8
5.2
—
—
—
0
0
10
19
5.39
3.85
1.2
1.2
6.04
7.95
g/l
—
5
14
7
8
8.90
3.79
1.6
1.0
—
—
—
0
0
10
21
4.87
3.58
1.3
1.1
—
—
—
0
0
283
2522
1.73
3.52
6.0
4.6
1.83
1.97
mu/l
1.38
270
2298
65
421
1.67
3.23
9.3
6.2
1.04
1.03
mmol/l
0.08
60
397
24
111
2.25
3.21
1.5
1.2
—
—
—
0
0
38
210
1.91
3.20
1.5
1.5
—
—
—
0
0
13
44
3.03
3.17
1.2
1.2
1.83
3.76
u/ml
—
6
17
322
3013
2.30
3.10
37.8
21.5
85.39
82.98
umol/l
0.39
322
2989
20
87
2.38
3.07
1.2
1.2
—
—
—
0
0
52
322
1.73
3.04
1.7
1.6
—
—
—
0
0
9
21
4.37
3.01
1.4
1.3
—
—
—
0
0
22
101
2.26
3.00
1.6
1.5
58.36
10.27
iu/ml
—
5
24
58
373
1.67
2.96
1.7
1.6
—
—
—
0
0
5
6
8.43
2.76
2.0
1.0
14.40
37.00
%
—
5
6
7
14
5.08
2.74
7.0
2.9
4140.29
1021.50
u/ml
—
7
14
57
374
1.63
2.69
10.8
7.4
95.19
95.01
%
0.11
51
362
54
350
1.65
2.67
1.2
1.3
—
—
—
0
0
62
418
1.59
2.62
2.0
1.7
—
—
—
0
0
9
25
3.67
2.59
1.2
1.1
—
—
—
0
0
16
69
2.38
2.52
2.9
6.8
11.36
11.65
mmol/l
0.11
11
62
16
69
2.38
2.52
2.9
6.8
105.27
105.32
mmol/l
0.01
11
62
68
474
1.54
2.49
1.6
1.7
1020.56
1189.15
nmol/l
0.96
52
370
16
70
2.35
2.45
1.4
1.1
—
—
—
0
0
15
64
2.41
2.42
1.3
1.1
526.00
268.50
u/ml
—
10
32
317
2985
1.92
2.41
18.0
12.1
27.10
27.96
u/l
0.43
311
2904
21
106
2.05
2.31
1.9
1.8
—
—
—
0
0
295
2732
1.60
2.29
8.2
6.5
40.17
39.83
mmol/mol
0.22
286
2542
20
100
2.06
2.26
1.5
1.2
—
—
—
0
0
10
35
2.91
2.22
2.2
2.3
—
—
—
0
0
5
9
5.62
2.22
8.0
4.3
—
—
—
0
0
46
301
1.61
2.21
1.6
1.6
—
—
—
0
0
11
42
2.67
2.16
1.1
1.3
—
—
—
0
0
20
102
2.02
2.15
1.6
3.6
1.38
2.46
ratio
0.81
11
63
50
338
1.56
2.10
3.3
5.0
241.67
48.86
ug/l
0.51
43
279
10
37
2.75
2.08
1.9
1.0
—
—
—
0
0
128
1038
1.37
2.08
4.5
3.5
49.75
50.36
mg/l
0.01
101
712
307
2886
1.66
2.05
23.5
14.9
—
—
—
0
0
10
38
2.68
2.02
1.3
1.2
—
—
—
0
0
129
1055
1.36
1.97
5.1
4.3
13.35
8.38
mg/mmol
0.37
94
702
5
11
4.60
1.95
1.0
1.2
—
—
—
0
0
5
11
4.60
1.95
1.0
1.0
—
—
—
0
0
49
337
1.53
1.91
1.2
1.4
—
—
—
0
0
23
130
1.83
1.87
2.3
2.3
—
—
—
0
0
116
941
1.35
1.85
3.8
3.2
0.65
0.80
ug/l
1.55
89
615
131
1083
1.34
1.84
4.4
3.5
7.59
8.25
mmol/l
0.89
114
929
76
577
1.41
1.81
3.4
3.2
2.46
2.44
mmol/l
0.34
69
527
7
23
3.09
1.81
1.1
1.8
43.69
34.77
%
—
7
23
20
110
1.87
1.77
1.6
1.7
191.30
226.63
pmol/l
0.87
20
104
8
30
2.71
1.73
1.5
1.2
—
—
—
0
0
17
89
1.96
1.73
1.2
1.2
—
3.89
—
0
7
322
3085
1.83
1.73
44.4
24.6
91.53
91.40
fl
0.20
322
3054
18
97
1.90
1.69
4.0
2.7
1.64
1.62
mg/l
0.04
18
87
322
3087
1.81
1.69
46.1
25.1
40.33
40.80
%
0.86
322
3054
322
3087
1.81
1.69
44.3
24.5
30.43
30.56
pg
0.54
322
3056
224
2016
1.33
1.67
4.8
3.7
15.19
14.93
pmol/l
0.87
211
1826
322
3089
1.80
1.66
44.8
24.8
134.37
137.79
g/l
3.14
322
3057
7
25
2.84
1.66
1.1
1.1
—
—
—
0
0
54
392
1.45
1.64
2.2
2.3
13.83
14.16
nmol/l
0.10
49
355
24
145
1.70
1.59
4.0
4.2
34.05
1762.78
u/ml
1.23
19
131
181
1590
1.30
1.58
6.1
5.4
2.20
2.76
ug/l
0.68
169
1418
34
226
1.56
1.56
4.5
6.1
25.18
24.19
mmol/l
0.74
29
213
102
835
1.32
1.49
1.5
1.4
—
—
—
0
0
94
1137
0.76
1.45
3.6
3.3
—
—
—
0
0
15
81
1.89
1.42
2.7
3.2
34.00
38.55
umol/l
0.30
15
73
291
2750
1.40
1.39
5.6
5.2
6.20
6.06
mmol/l
0.61
276
2515
302
2878
1.44
1.32
6.6
5.8
2.52
2.62
mmol/l
1.29
288
2654
6
25
2.42
1.25
1.5
4.8
379.83
1142.68
mg
—
6
25
37
265
1.44
1.23
4.4
4.6
1.71
0.61
%
0.43
14
98
30
206
1.50
1.22
3.0
4.5
—
—
—
0
0
8
38
2.13
1.19
1.3
1.2
—
—
—
0
0
38
277
1.42
1.16
4.6
4.4
0.79
0.96
%
0.25
14
102
8
39
2.08
1.16
2.0
3.9
8.60
6.90
nmol/l
—
8
39
5
20
2.52
1.15
1.2
1.0
—
—
—
0
0
23
153
1.54
1.09
1.3
1.3
—
—
—
0
0
5
21
2.40
1.09
1.2
1.1
—
—
—
0
0
5
21
2.40
1.09
2.6
2.7
—
—
—
0
0
11
59
1.89
1.08
1.2
1.2
—
—
—
0
0
7
33
2.14
1.06
1.1
1.1
—
—
—
0
0
7
33
2.14
1.06
1.0
1.2
—
—
—
0
0
7
33
2.14
1.06
3.0
1.9
11.00
11.03
mmol/l
—
7
33
19
122
1.59
1.05
1.6
1.3
—
—
—
0
0
296
2834
1.34
1.04
5.7
5.2
4.34
4.48
mmol/l
1.69
285
2631
5
23
2.19
0.98
1.2
1.0
—
—
—
0
0
7
36
1.96
0.97
1.0
1.4
25.00
30.40
ng/l
—
7
36
9
51
1.79
0.95
1.0
1.4
—
—
—
0
0
131
1159
1.21
0.95
5.2
3.9
47.00
36.99
ng/l
0.24
96
875
13
79
1.67
0.89
1.2
1.5
—
—
—
0
0
45
356
1.30
0.86
5.2
3.0
4.62
6.62
e9/l
0.65
40
308
19
129
1.50
0.85
1.1
1.2
74.46
95.52
u/ml
—
5
46
12
74
1.64
0.79
1.8
4.8
—
—
—
0
0
22
158
1.42
0.76
2.2
1.9
0.80
2.30
ug/l
1.28
22
135
292
2816
1.26
0.76
5.5
5.1
1.38
1.38
mmol/l
0.03
281
2586
9
53
1.72
0.76
1.1
1.0
—
—
—
0
0
6
107
0.55
0.74
1.0
1.1
1.36
1.50
g/l
—
6
107
6
108
0.55
0.73
1.0
1.1
0.88
0.89
g/l
—
6
108
13
84
1.57
0.73
1.7
1.3
4.25
8.81
u/l
3.04
13
68
132
1194
1.17
0.72
2.1
1.9
1.37
1.35
mmol/l
0.08
125
1001
7
40
1.77
0.71
3.1
3.1
105.14
104.65
mmol/l
—
7
40
7
40
1.77
0.71
3.1
3.1
3.93
4.04
mmol/l
—
7
40
123
1110
1.17
0.68
5.5
3.5
0.00
0.02
estimate
0.69
28
259
19
136
1.42
0.68
2.4
3.2
—
—
—
0
0
22
164
1.37
0.64
1.5
1.6
—
—
—
0
0
34
271
1.28
0.64
4.9
5.0
0.00
0.15
%
1.24
11
84
12
79
1.54
0.63
2.8
2.2
127.14
132.52
g/l
—
7
63
8
50
1.61
0.61
3.6
2.9
5.65
4.00
e9/l
—
8
50
5
30
1.68
0.61
1.0
1.4
—
—
nmol/l
—
0
0
8
51
1.58
0.61
1.1
1.1
—
—
—
0
0
11
162
0.67
0.60
6.3
4.3
—
—
—
0
0
0
22
0.00
0.59
0.0
1.0
—
—
—
0
0
33
265
1.27
0.59
2.6
2.4
35.33
9.79
ug/l
0.49
27
235
0
23
0.00
0.58
0.0
4.5
—
7.58
—
0
23
0
23
0.00
0.58
0.0
4.4
—
16.63
—
0
23
74
649
1.18
0.58
5.1
3.6
1.02
1.02
kg/l
0.28
53
436
32
257
1.27
0.58
5.0
4.5
0.00
0.18
%
—
8
84
10
65
1.55
0.56
6.3
3.7
—
—
—
0
0
6
39
1.55
0.53
3.5
3.2
1.19
1.19
mmol/l
—
6
39
28
229
1.24
0.45
2.6
2.1
0.00
0.06
estimate
—
6
50
19
149
1.29
0.43
1.5
1.8
0.29
0.30
mg/l
—
10
81
5
32
1.57
0.42
1.4
4.0
—
—
—
0
0
8
58
1.39
0.42
3.0
2.7
—
—
—
0
0
8
59
1.36
0.41
1.1
1.3
15.01
22.77
iu/l
—
8
46
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
14
107
1.32
0.38
1.4
1.2
—
—
—
0
0
9
70
1.29
0.37
3.3
2.7
69.67
58.73
%
—
9
70
19
153
1.26
0.36
1.0
1.1
—
—
—
0
0
275
2696
1.10
0.27
4.8
4.4
1.28
1.32
mmol/l
0.57
265
2471
10
77
1.31
0.26
1.6
1.4
15.79
36.11
u/l
—
10
67
25
216
1.17
0.26
1.3
1.4
—
—
—
0
0
10
78
1.29
0.24
1.4
2.0
—
—
—
0
0
10
78
1.29
0.24
1.4
2.4
—
—
—
0
0
10
78
1.29
0.24
1.4
2.4
—
—
—
0
0
100
1055
0.93
0.24
3.8
3.7
—
0.60
—
0
5
32
286
1.13
0.22
1.9
1.4
—
—
—
0
0
10
79
1.27
0.22
1.4
2.5
—
—
—
0
0
5
40
1.25
0.22
1.4
1.2
474.80
1823.35
e6/l
—
5
26
0
12
0.00
0.21
0.0
1.7
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
14.21
—
0
13
6
49
1.23
0.20
2.3
4.1
7.37
11.75
pmol/l
—
6
49
6
53
1.13
0.19
1.2
1.6
—
—
—
0
0
6
53
1.13
0.19
1.2
1.6
—
—
—
0
0
6
53
1.13
0.19
1.2
1.6
—
—
—
0
0
6
53
1.13
0.19
1.2
1.6
—
—
—
0
0
7
58
1.21
0.18
1.3
1.1
1.50
1.53
g/l
—
7
51
23
256
0.89
0.16
2.7
4.8
7.37
7.36
ph
0.33
12
190
8
70
1.15
0.16
1.5
2.6
—
—
—
0
0
9
83
1.09
0.14
1.8
1.6
—
—
—
0
0
83
800
1.05
0.12
6.8
3.8
0.00
0.01
estimate
0.74
30
272
20
217
0.92
0.09
8.8
3.7
—
—
—
0
0
10
112
0.89
0.07
1.1
1.6
—
—
—
0
0
82
803
1.03
0.05
5.4
3.0
0.00
0.00
estimate
-0.00
28
233
61
603
1.01
0.01
1.6
1.8
472.63
22500418.22
pmol/l
0.50
49
520
10
94
1.07
0.01
5.3
9.7
—
—
—
0
0
5
56
0.89
0.00
3.2
2.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.8
—
9.00
—
0
5
7
77
0.91
-0.00
4.4
3.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
40.83
—
0
6

Mortality – FinRegistry

↥

Association

Association between endpoint M13_BURSELBOWOTH and mortality.

Females

Parameter HR [95% CI] p-value
M13_BURSELBOWOTH 1.937 [1.38, 2.72] < 0.001
Birth year 0.994 [0.99, 1.0] 0.187

During the follow-up period (1.1.1998 — 31.12.2019), 74 out of 341 females with M13_BURSELBOWOTH died.

Males

Parameter HR [95% CI] p-value
M13_BURSELBOWOTH 1.873 [1.51, 2.32] < 0.001
Birth year 0.986 [0.98, 1.0] 0.003

During the follow-up period (1.1.1998 — 31.12.2019), 294 out of 1209 males with M13_BURSELBOWOTH died.

Mortality risk

Mortality risk for people of age

years, who have M13_BURSELBOWOTH.

N-year risk Females Males
1 0.152% 0.299%
5 1.068% 2.092%
10 2.569% 4.976%
15 5.234% 9.559%
20 9.504% 16.253%

Relationships between endpoints

↥

Index endpoint: M13_BURSELBOWOTH – Other bursitis of elbow

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data